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Abstract 
Background: Crohn’s disease (CD), a transmural and segmental chronic bowel 
inflammation, can affect the entire gastrointestinal tract. In CD, symptoms sometimes fail 
to correlate with inflammation detected by endoscopy. Conventional laboratory markers 
such as serum C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) are 
insufficiently sensitive to reveal intestinal inflammation. The fecal neutrophil-derived 
proteins calprotectin and lactoferrin have proven useful surrogate markers of intestinal 
inflammation and can reliably distinguish between bowel inflammation and 
noninflammatory functional conditions. The correlation of these markers with CD 
endoscopic activity is, however, insufficiently examined. The aim of this study was to 
compare fecal calprotectin and lactoferrin concentrations to clinically, endoscopically, and 
histologically assessed CD activity. During tumor necrosis factor-alpha (TNFα) blocking 
therapy, we explored the suitability of these proteins as surrogate markers of mucosal 
healing. Furthermore, we studied changes in the number and expression of effector and 
regulatory T cells in bowel biopsy specimens during anti-TNFα therapy. 
 
Patients and methods: Adult CD patients referred for ileocolonoscopy for various reasons 
were recruited. The number of endoscopies performed was 106 for 77 patients (Study I). 
Clinical disease activity was assessed with the Crohn’s disease activity index (CDAI) and 
endoscopic activity with both the Crohn’s disease index of severity (CDEIS) and the 
simple endoscopic score for Crohn’s disease (SES-CD). Patients provided stool samples 
for measurements of calprotectin and lactoferrin, and blood samples for CRP.  To explore 
correlations of fecal markers with histologic CD activity (Study II), we obtained biopsy 
specimens from the most severely affected lesions in the ileum and in four segments of the 
colon during 87 endoscopies on 61 patients. A histologic score was calculated based on the 
findings in the biopsy specimens. 
Prospective Study III explored changes in endoscopic and clinical scores and fecal 
markers during anti-TNFα therapy for 15 adult CD patients. After baseline 
ileocolonoscopy, 14 patients received induction therapy with parenteral infliximab, and 
one patient received subcutaneous adalimumab. At the time of baseline endoscopy and 2, 
8, and 12 weeks after the first treatment, each patient provided a diary for calculation of the 
CDAI, and samples for measurements of serum CRP, fecal calprotectin, and lactoferrin. 
Endoscopic and histologic responses to therapy were evaluated at 12 weeks after beginning 
of therapy. In Study IV, for further evaluation of alerations in mucosal inflammatory 
activity by detecting changes in the number and expression of effector and regulatory T 
cells, two biopsy specimens were taken from the most severely diseased lesions in the 
ileum and the colon during the baseline and post-treatment endoscopies. The control group 
comprised 14 patients without signs of endoscopic or histologic intestinal inflammation.  
 
Results: CDEIS and SES-CD correlated significantly with fecal calprotectin (Spearman’s 
rank order correlation coefficient r=0.729 for CDEIS and r=0.699 for SES-CD, both 
p<0.001) and lactoferrin (r=0.773 and r=0.751, both p<0.001). Correlations of CDEIS with 
CDAI (r=0.381) and CRP (r=0.553, both p<0.001) were weaker.  
 
 
 
 
12
     Both fecal markers were significantly lower in patients with endoscopically inactive 
(CDEIS <3) than with active disease (CDEIS ≥3) (p<0.001). In detecting endoscopically 
active disease, the sensitivity, specificity, positive predictive value (PPV), and negative 
predictive value (NPV) for calprotectin  ≥200 μg/g were 70%, 92%, 94%, and 61%; for 
lactoferrin ≥10 μg/g they were 66%, 92%, 94%, and 59%. Accordingly, the sensitivity, 
specificity, PPV, and NPV for CRP >5 mg/l were 48%, 91%, 91%, and 48%, and for 
CDAI with a cutoff 150 these were 27%, 94%, 91%, and 40%.    
     Fecal markers were significantly higher in active colonic (both p<0.001) or ileocolonic 
(calprotectin p=0.028, lactoferrin p=0.004) than in ileal disease. In ileocolonic or colonic 
disease, colon histology score correlated significantly with fecal calprotectin (r=0.563) and 
lactoferrin (r=0.543). In ileal disease, however, histology score failed to correlate with 
fecal markers (r=0.311 for calprotectin and r=0.291 for lactoferrin). Patients with normal 
fecal calprotectin or lactoferrin had significantly lower endoscopic (p<0.001) and 
histologic scores (p<0.001) than did those with elevated fecal markers. 
In patients receiving anti-TNFα therapy, median CDEIS decreased from baseline level 
13.0 (range 1.8-25.3) to 4.8 (0.0-11.2), p=0.002.  Accordingly, fecal calprotectin decreased 
from 1173 μg/g (88-15326) to 130 μg/g (13-1419) and lactoferrin from 105.0 μg/g (4.2-
1258.9) to 2.7 μg/g (0.0-228.5), both p=0.001.  The CDAI fell from 158 (49-605) to 66 
(24-202, p=0.005) and CRP from 10 mg/l (<5-54) to <5 mg/l (<5-6, p=0.005). Colon 
histology score declined from 23 (0-38) to 11 (0-25, p=0.002) and ileal histology score 
from 7 (0-11) to 4 (0-9, p=0.022).  
Compared to controls, both before and after anti-TNFα therapy, the numbers of 
interleukin (IL) 17+ cells and Foxp3+ cells in ileal specimens were significantly increased 
(all p<0.05). Accordingly, in the colon, the number of IL-17+ cells was increased before 
and after the therapy (p=0.015 and p=0.042), and Foxp3+ cells were increased compared to 
control numbers only after the treatment (p=0.032).  Changes in the number of IL-17+ cells 
and Foxp3+ cells during therapy were nonsignificant, but the relation of ileal IL-17+ cells to 
CD4+ cells decreased significantly during anti-TNFα treatment (p=0.047). The relation of 
IL-17+ cells to Foxp3+ cells was higher in the patients’ baseline specimens than in their 
post-treatment specimens (p=0.038).  
 
Conclusions: For evaluation of CD activity, based on endoscopic findings, more sensitive 
surrogate markers than CDAI and CRP were fecal calprotectin and lactoferrin. Fecal 
calprotectin and lactoferrin were significantly higher in endoscopically active disease than 
in endoscopic remission. In both ileocolonic and colonic disease, fecal markers correlated 
closely with histologic disease activity. In CD, these neutrophil-derived proteins thus seem 
to be useful surrogate markers of endoscopic activity.  
     During anti-TNFα therapy, fecal calprotectin and lactoferrin decreased significantly. 
Furthermore, endoscopically confirmed mucosal healing was associated with reduced 
mucosal IL-17/CD4 cell ratio. The anti-TNFα treatment was also reflected in a decreased 
IL-17/Foxp3 cell ratio, which may indicate improved balance between effector and 
regulatory T cells with treatment. 
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Introduction 
Crohn’s disease (CD), ulcerative colitis (UC), and colitis unclassified, all being the 
consequence of chronic inflammatory reactions in the gastrointestinal tissue, are 
collectively defined as inflammatory bowel disease (IBD). These are chronic diseases 
arising from interactions between immunoregulatory, genetic, and environmental factors. 
While UC is limited to the colon, CD can affect the whole gastrointestinal tract.  
In CD, symptoms do not always correlate with inflammatory activity in the bowel: 
Patients with highly active inflammation may be nonsymptomatic or may have adapted to 
their chronic symptoms, and some patients may show symptoms regardless of mucosal 
healing.  In these situations, endoscopy may help in treatment decisions.  Endoscopy with 
biopsies is the mainstay in the diagnosis of both CD and UC and important in the 
assessment of disease activity and monitoring of treatment.  New endoscopy techniques of 
the intestine such as wireless capsule endoscopy now allow direct and objective assessment 
of mucosal healing. Mucosal healing is becoming a target for new CD therapies that 
associate with better outcome of the disease with fewer hospitalizations or need for 
surgery. However, due to the costs and to limited endoscopic capacity, the need is strong 
for reliable surrogate markers to monitor disease activity. Several clinical activity scores 
are widely used, but they are subjective and often underestimate the inflammation. 
Conventional laboratory tests such as hemoglobin, C-reactive protein (CRP), and 
erythrocyte sedimentation rate (ESR) are insufficiently sensitive to detect intestinal 
inflammation. 
Bowel contents are in close contact with intestinal mucosa and can take up molecules 
that are measurable from stool samples and thus serve as markers of inflammation.  The 
fecal neutrophil-derived proteins calprotectin and lactoferrin have several features of an 
ideal test for detecting inflammation: They are nonivasive, simple, and low in cost. They 
allow serial monitoring of disease activity and of treatment success, and can even serve in 
predicting clinical relapse in nonsymptomatic patients. The utility of these markers in 
distinguishing IBD from non-inflammatory conditions such as irritabile bowel syndrome is 
well documented.  Correlation of these markers with validated endoscopic scores in CD is, 
however, insufficiently studied. 
      This thesis aims to determine the correlation of fecal calprotectin and lactoferrin with 
endoscopic, histologic, and clinical disease activity in CD and the suitability of these fecal 
proteins as surrogate markers of disease activity. Another aim was to study how these fecal 
markers serve as surrogate markers of treatment monitoring in CD compared to endoscopy 
and histology. Finally, during anti-tumor necrosis factor alpha (TNFα) therapy, focusing in 
interleukin-17 (IL-17)-secreting cells, we studied mucosal effector and regulatory T-cell 
balance, which may reflect intestinal inflammatory activity. 
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 Review of the literature 
Crohn’s disease— also called terminal ileitis, regional enteritis, granulomatous ileitis, 
hyperplastic ileitis, chronic ulcerative ileitis,  and intestinal phlegmon—is named after the 
American Dr. Burrill Crohn, who with his colleagues Ginzburg and Oppenheimer 
described regional enteritis over 75 years ago (Crohn et al 1932).  CD is a transmural 
inflammatory disease of the gastrointestinal mucosa that can affect any part of the entire 
gastrointestinal (GI) tract (Baumgart and Sandborn 2007). It is characterized by a chronic 
course in which phases of remission are interrupted by unpredictable acute episodes 
(relapses). Some patients may have continously active inflammation (chronically active 
disease). 
     A slight female preponderance in CD occurs, depending however, on age and 
geographic region (Brant and Nguen 2008). CD typically manifests in young adolescents, 
and approximately 20% of all IBD patients develop symptoms in childhood (Heyman et al 
2005, Nikolaus and Schreiber 2007). The highest incidence rates and prevalences occur in 
developed countries with a yearly incidence of up to 16.3/100 000 and a prevalence of 
213/100 000 (Loftus 2004, Lapidus 2006, Baumgart and Carding 2007, Bernstein and 
Shanahan 2008). One estimates that annually Europe has 23,000 to 41,000 new CD cases 
(Loftus 2004). A distinct north-south gradient occurs within Europe, but the incidence in 
southern Europe has increased in recent years (Shivananda et al 1996). At diagnosis, age 
below 40 years, presence of perianal disease, and initial need for corticosteroid therapy are 
factors predictive of a more disabling disease course (Beaugerie et al 2006). The life-
expectancy of patients with CD seems to be slightly below average (Jess et al 2002). 
1 Etiology and pathogenesis of Crohn’s disease 
Although the understanding of immunological mechanisms has developed markedly during 
recent years, CD etiology and pathogenesis is not fully known. The most widely accepted 
hypothesis is that a disturbed interaction of the host immune system with its commensal 
microflora and other luminal antigens leads to damage of the bowel mucosa (Baumgart and 
Carding 2007, Brown and Mayer 2007).  
1.1 Genetics 
An inherited predisposition is important in the pathogenesis of CD, with CD more 
prevalent in Jewish people than in any other ethnic group. According to three large twin 
studies, the pooled concordance is 36% in monozygotic twins (Tysk et al 1988, Orholm et 
al 2000, Thompson et al 1996, Russell and Satsangi 2004). Patients have a first-degree 
relative with IBD in 2 to 22% of cases (Gaya et al 2006). The discovery of the gene 
encoding caspase-activating recruitment domain 15 (CARD15)—also known as the 
nucleotide oligomerisation domain 2 (NOD2)—has been important in the understading of 
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interactions between genetic factors and bacterial flora (Hugot et al 2001, Gaya et al 
2006). It plays a key role in innate host defense, and mutations of this gene are strongly 
associated with ileal CD and especially with stricturing disease. However, ethnic variation 
in the contribution of this gene occurs; in Europe, allelic frequency is lower in northern 
countries (about 5% in Finland) than in central or southern Europe (9-14%) (Heliö et al 
2003, Gaya et al 2006). Furthermore, recent studies have revealed that several 
polymorphisms of the IL-23 receptor (IL-23R) gene locus are associated with CD 
susceptibility (Duerr et al 2006). Recently, a genome-wide association study combining 
data of three studies defined more than 30 distinct CD susceptibility loci (Barrett et al 
2008). 
1.2 Environmental factors 
Several environmental factors such as diet, bacteria, viruses, use of nonsteroidal 
antiinflammatory drugs (NSAIDs), and high hygiene level have been studied as CD 
triggers.  Of life style factors, the effect of smoking in CD is best documented: it adversely 
affects the course of the disease, raises exacerbation rates, promotes complications and risk 
for surgery (Johnson et al 2005). 
1.3 Role of immune response 
Mucosal host defense can be divided into innate immune response and adaptive immune 
response. The innate immune system is a nonspecific defense against pathogens by the 
macrophages, dendritic cells, natural killer (NK) cells, neutrophils, and the complement 
system. Responses of these components are inborn and not tailored to a particular 
immunological challenge. In the adaptive immune system, the main cells are T and B 
lymphocytes. Adaptive immune response is a slower and secondary response and is more 
specifically tailored through function of these cells. In CD, abnormalities occur in the 
mucosal barrier, innate immune response, and adaptive immune system.  
      A defect in the intestinal mucosal barrier can lead to loss of tolerance to commensal 
microbial flora. In the healthy gut, the  mucosal barrier—consisting of secreted and cell-
surface mucins and a single layer of intestinal epithelial cells (IECs)— protects the 
mucosal immune system (Brown and Mayer 2007). Secreted IgA from mucosal plasma 
cells coats and neutralizes pathogens, and IECs can secrete a number of cytokines and 
chemokines. Defensins and cryptidins secreted from Paneth cells in the small intestine act 
as antimicrobial agents preventing microbial invasion into the crypt microenvironment. In 
ileal CD, expression of α-defensins is reportedly reduced compared to that of unaffected 
ileum and to the ileum from healthy controls (Wehkamp et al 2007). 
      Antigen-presenting cells (APCs) such as dendritic cells express a wide spectrum of 
pattern-recognition receptors (PRRs). Two types of PRRs are involved in this host 
response to microbes in the intestinal tract: membrane-associated toll-like receptors (TLRs) 
and cytosolic NOD proteins. In healthy IECs, TLR3 and TLR5 are constitutively expressed 
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and TLR2 and TLR4 barely detectable, whereas in active CD, TLR3 is downregulated and 
TLR4 is overexpressed (Baumgart and Carding 2007). NOD2, which is preferentially 
expressed in macrophages, dendritic cells, and Paneth cells, recognizes muramyl dipeptide, 
the smallest structure of bacterial wall peptidoglycan, and mediates the interaction between 
the innate immune response and the host. Mutations in the NOD2 gene are associated with 
a decrease in nuclear factor-κB activation (NF-κB), leading to an inappropriate response to 
muramyl dipeptide (Inohara et al 2003).  
      In IBD, dendritic cells may falsely recognize commensal bacteria as pathogens and are 
activated, promoting differentiation of naïve T cells (Th0) into effector T cells (Th1, Th17, 
and Th2) and natural killer T cells. In CD, naïve T cells preferably differentiate into Th1, 
producing interferon-γ (IFN-γ) and IL-12, whereas in UC, differentiation of Th0 cells into 
Th2 cells predominates. IL-23, produced by innate immune cells, activates Th17-type T 
cells and seems to be imporant in maintaining Th17 cell responses (Caprioli et al 2008). In 
active inflammation, effector T cells predominate over regulatory T cells. These activated 
effector cells secrete proinflammatory cytokines and stimulate macrophages to secrete 
large amounts of cytokines such as TNFα, IL-1, and IL-6. Furthermore, defects in 
regulatory T-cell function and in T-cell apoptosis can occur (Brown and Mayer 2007).  A 
marker for regulatory T cells is the forkhead transcription factor Foxp3 expressed mainly 
in regulatory T cells. The Foxp3 transcription seems to be upregulated both in active 
disease and in CD remission (Hölttä et al 2008). 
     Neutrophils are among the body’s main cellular components for the destruction of 
microorganisms. The majority of neutrophils is storaged in the bone marrow. In response 
to inflammatory messengers such as cytokines, neutrophils are released from the bone 
marrow into the blood stream and access inflamed tissues. Neutrophils, important 
contributors to recruitment and activation of APCs, cause tissue damage through the 
release of nonspecific inflammatory mediators and secrete cytokines and multiple anti-
microbial agents such as calprotectin, lactoferrin, neutrophil elastase, myeloperoxidase, 
and lysozyme (Nathan 2006). In CD, changes in neutrophil function include defective 
neutrophil migration due to impaired chemotaxis (Harbord et al 2006). Furthermore, 
impaired apoptosis of neutrophils can result in an extended lifespan for these cells and may 
promote tissue damage (Brown and Mayer 2007).  
2 Disease location and classification by phenotype 
At diagnosis, in approximately 25% of patients both the terminal ileum and colon are 
affected, about 45% show exclusively terminal ileitis, and in about 25% only the colon is 
involved (Louis et al 2001, Baumgart and Sandborn 2007). In up to 10% of CD patients 
the disease may affect the ileum out of reach of ileocolonoscopy or involve the more 
proximal small bowel (Stange et al 2006). Small intestinal and upper GI disease is more 
common in patients diagnosed before age 20, whereas colonic disease is diagnosed more 
frequently in late-onset (>40 years) disease (Polito et al 1996). Interestingly, in contrast to 
older children or adults, almost all children diagnosed before age eight have colonic 
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disease (isolated or in combination to small bowel disease) (Heyman et al 2005, Silverberg 
et al 2005).  
      Typical presentations include discontinous involvement of various portions of the GI 
tract and development of disease complications such as strictures, fistulas, or abscesses. 
The Vienna classification has been developed to describe the distinct clinical CD 
phenotypes with respect to disease location and occurrence of complications (Gasche et al 
2000). Age at diagnosis (A: A1 <40 years, A2 ≥40 years), disease location (L: L1 ileum, 
L2 colon, L3 ileocolon, L4 upper GI), and disease behavior (B) are three categories for 
allocating patients. Disease behavior is classified as non-stricturing and non-penetrating 
(inflammatory, B1), stricturing (B2), or penetrating (B3) (Gasche et al 2000).  Anatomical 
location remains relatively stable over the course of the disease, but disease behavior may 
change over time, with the most prominent change being from inflammatory to either 
stricturing or penetrating (Louis et al 2001, Cosnes et al 2002). According to a Norwegian 
5-year follow-up study of new CD cases, however, changes in disease location were 
apparent at 5 years in 13.5% and in disease behavior in 17.5% of patients (Henriksen et al 
2007). Stricturing complications were evident in 64% of ileal CD patients but in only 6% 
of patients with colonic CD.  
      An update of the Vienna classification was proposed in Montreal, including a revised 
age category and upper GI tract and perianal disease modifiers for disease location and 
behavior (Silverberg et al 2005, Satsangi et al 2006). “Upper GI tract” in the classification 
means any disease proximal to the terminal ileum. 
3 Diagnosis  
No single specific test exists for Crohn’s disease. Lennard-Jones and Shivananda with  the 
European IBD Study Group (1997)  have defined widely accepted criteria for diagnosis of 
CD, including macroscopic discontinuity of disease, transmural inflammation (shown by 
fistula or abscess formation outside the gut or by examination of a surgical specimen), 
fibrosis (evidenced by stricture formation), and histologic criteria (lymphoid aggregates, 
discontinuous inflammation, or granulomas). According to these criteria, CD is established 
if granuloma with at least one criterion is present, or, in the absence of granuloma, if three 
criteria are present. CD is probable with two criteria without granulomas (Lennard-Jones 
and Shivananda 1997). These criteria seem, however, too strict in early CD and may be 
biased towards complicated CD (Reinisch 2007). The current view is that diagnosis is 
established by a broadly defined combination of clinical presentation, endoscopic 
appearance, histology, radiology, and surgical findings (Stange et al 2006, Baumgart and 
Carding 2007).  
3.1 Clinical presentation 
Clinical presentation depends on disease location. Chronic diarrhea is the most common 
symptom, affecting up to 85% of patients (Nikolaus and Schreiber 2007), with abdominal 
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pain occurring in about 70% and weight loss in about 60% (Lennard-Joes and Shivananda 
1997). Fever, rectal pain, and fatigue can also be present. Blood or mucus or both can be 
present in stools in approximately 50% of patients and perianal fistulas in 10% at diagnosis 
(Stange et al 2006). Children can present with growth retardation. A considerable number 
(up to 30%) of IBD patients may suffer from extraintestinal manifestations such as 
peripheral arthropathy, axial arthritis, ocular (uveitis, episcleritis), cutaneous (erythema 
nodosum, pyoderma gangrenosum), or hepatobiliary disease (primary sclerosing 
cholangitis) (Stange et al 2006).  
      In physical examination, a CD patient may appear underweight. Inspection of the oral 
mucosa may reveal small aphthous ulcers. Abdominal bowel sounds may be abnormal, and 
on palpation, pain or abnormal mass detectable. Patients with ileal involvement can present 
with pain in the right lower abdomen. Evidence of perianal fistulae or fissures can be 
detectable upon inspection of the anal region, and gross abnormalities of the rectal mucosa 
and hematochezia detectable in rectal examination. 
      In diagnostic work-up, stool tests for investigation of pathogenic bacteria and parasites 
are necessary to differentiate IBD from infectious colitis. Blood tests may reveal anemia or 
elevated leukocyte and platelet counts. Serum CRP can be elevated and hypoalbuminemia 
can be present. 
 3.2 Endoscopy 
The mainstay for IBD diagnosis is ileocolonoscopy. Initial endoscopy should intubate the 
terminal ileum, and in practice ileocolonoscopy with biopsies has been achieved in at least 
85% of patients. Inflamed mucosal areas alternating with noninflamed mucosal surfaces 
(“skip lesions”) is a typical finding. The rectum can be spared. Small, deep aphthous ulcers 
or longitudinal, polygonal ulcers are characteristic configurations. In chronic disease, a 
patchy, cobblestone pattern is often visible in the terminal ileum (Nikolaus and Schreiber 
2007), which is a typical location for strictures. Fistulas, fissures, or anal skin tags can be 
evident. Ileocolonoscopy is time-consuming, expensive, requires bowel preparation, and is 
unpleasant for patients. When severe active inflammation is present, initial flexible 
sigmoideoscopy may be safer (due to risk for bowel perforation), with ileocolonoscopy  
postponed until clinical condition is improved.      
      Esophagogastroduodenoscopy (EGD) is often in clinical practice reserved for CD 
patients with upper GI symptoms, but some experts suggest that it should be performed at 
least once on all newly diagnosed CD patients (Hommes and van Deventer 2004). EGD 
can be useful in patients with their colitis unclassified:  Focal active gastritis in the absence 
of ulceration may be a CD feature (Stange et al 2006). 
      Radiographic techniques were formerly the only available techniques for examination 
of the entire small bowel, but during recent years, small bowel wireless capsule endoscopy 
(WCE), double-balloon enteroscopy (DBE), and magnetic resonance imaging (MRI) 
enterography have made radiation-free examination of the whole small bowel possible. 
WCE, a novel technique for examining the entire small bowel and directly visualizing 
small bowel lesions, is useful in suspicion of small bowel CD and in assessment of small 
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bowel CD extension and severity. In patients with unclassified colitis, WCE may help in 
distinguishing between UC and CD. WCE is superior to small bowel follow-through 
(SBFT), barium enteroclysis (SBE), and conventional computed tomography (CT) in 
establishing the diagnosis and estimating disease extent and is widely considered a first-
line examination after negative colonoscopy and EGD (Sandrasegaran et al 2008). In many 
centers, WCE has replaced more invasive push enteroscopy, but WCE is limited by its cost 
and its inability to provide tissue samples or therapy.  Furthermore, with WCE, localization 
of lesions is troublesome. Contraindications for WCE are suspected or documented 
intestinal obstruction or strictures. 
      Double–balloon enteroscopy is a new technique that makes it possible to reach lesions 
throughout the entire small bowel (Yamamoto et al 2001). The scope may be inserted by 
either an oral or anal route. DBE is not widely available, and its use in CD is at present 
mainly therapeutic, i.e., dilation of strictures.  
3.3 Imaging techniques 
Due to its ubiquitous availability, barium studies SBFT and intubation technique-requiring 
SBE are still considered the current standards for assessment of small bowel CD (Stange et 
al 2006), although they cause a radiation burden and are therefore not suitable for follow-
up. Compared to SBFT and SBE, cross-sectional CT gives additional information on the 
bowel wall and adjacent structures. CT-enteroclysis is superior to conventional enteroclysis 
in depicting CD-associated intra- and extramural abnormalities (Engin 2008), and 
quantitative measures of bowel enhancement at CT-enterography correlate with endoscopy 
and histology in ileal CD (Colombel et al 2006). Because of its radiation burden, CT is 
unsuitable for repeated use. In some centers either MRI-enterography or MRI-enteroclysis 
has already replaced radiation techniques in assessment of small bowel CD. These 
procedures can be performed repeatedly and are thus suitable for follow-up of CD patients. 
Small bowel MRI provides information on disease activity and detects extramural 
complications (abscesses, fistulas, sacroilitis). In detecting inflammatory small bowel 
changes, the sensitivity (95%) and the specificity (93%) of MRI-enteroclysis are superior 
to those of SBE (85% and 77%) (Rieber et al 2000); also in assessment of perianal fistulas 
MRI is a sensitive technique and in the setting of clinical trials is considered mandatory 
(Caprilli et al 2006). Ultrasound may be of benefit in detecting ileal disease and extramural 
complications of CD, but does not provide information on the extent of the disease and is 
operator-dependent (Stange et al 2006). 
3.4 Histology 
Histologic examination is routinely used for the diagnosis of IBD and is helpful in the 
histologic distinction between UC and CD. In UC, inflammation is limited to the colon and 
is superficial, whereas in CD it is generally transmural, multifocal, and may contain 
granulomas. 
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      For the initial diagnosis of CD, during ileocolonoscopy multiple mucosal biopsies 
should be obtained from all segments of the colon (right, transverse, the left colon and 
sigmoid, and rectum) and the ileum. Biopsy samples preferably come both from areas 
affected by the disease and from areas unaffected (Stange et al 2006). Typical histologic 
changes in CD in mucosal biopsy specimens are focal (segmental or discontinuous) crypt 
architectural abnormalities in conjunction with focal or patchy chronic inflammation 
(presence of lymphocytes or plasma cells), granulomas, and mucin preservation at active 
sites (Jenkins et al 1997, Stange et al 2006). The same features and additionally an 
irregular villous architecture can serve in analysis of ileal biopsy samples. Granulomas—
defined as a collection of epitheloid histiocytes—are regarded as a corroborating feature of 
CD when present in the lamina propria without association with active crypt injury 
(Mahadeva et al 2002). Crypt-associated granulomas can occur also in UC and are a less 
reliable feature in discrimination between UC and CD (Mahadeva et al 2002). The 
presence of granuloma is also the central histologic criterion among Lennard-Jones criteria 
(Lennard-Jones and Shivananda 1997). The transmural character of CD inflammation can 
be identified only when surgical samples are available. Other microscopic features  
detectable in surgical specimens of CD patients are aggregated inflammatory pattern, 
transmural lymphoid hyperplasia, submucosal thickening, fissures, sarcoid granulomas 
(including in lymph nodes), abnormalities of the enteric nervous system (submucosal nerve 
fiber hyperplasia and ganglionitis), and relatively unchanged epithelial mucin preservation 
(Stange et al 2006).  
 
4 Treatment 
When treating active CD, a clinician has to consider the disease activity, site (ileal, 
ileocolonic, colonic, or other), and disease behavior (inflammatory, stricturing, or 
fistulating). Seldom, in mild disease, is no treatment an option. Smoking cessation is 
associated with a 65% reduction in risk for relapse and should be encouraged in all 
smokers with CD (Cosnes et al 2001, Johnson et al 2005). 
4.1 Medical therapy 
Medical therapy for CD can be divided into induction and maintenance of remission.  
4.1.1 Corticosteroids 
Use of corticosteroids in CD is based on two placebo-controlled trials showing the 
effectiveness of oral corticosteroids in induction of clinical remission (Summers et al 1979, 
Malchow et al 1984, Irving et al 2007). Most IBD patients initially respond to the first 
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course of corticosteroid therapy, but about half will be either steroid-resistant or steroid-
dependent at one year (Munkholm et al 1994, Faubion et al 2001). Importantly, mucosal 
healing is achieved in only about a third of CD patients treated with corticosteroids 
(Modigliani et al 1990, Landi et al 1992). Corticosteroids play no role in maintaining 
remission. 
      In mildly active ileocecal CD, budesonide is the preferred treatment (Greenberg et al 
1994, Travis et al 2006). This corticosteroid has an effective first-pass hepatic metabolism, 
and its pH- and time-dependent formulation enables a targeted release to the terminal ileum 
and right colon. Budesonide is associated with fewer systemic side-effects than are 
systemic corticosteroids. In moderately active disease, induction of remission can be 
achieved with either budesonide (ileal and ileocecal CD or disease limited to the proximal 
colon) or systemic corticosteroids. Severely active ileocecal disease or moderate to severe 
extensive small bowel CD should be treated initially with systemic corticosteroids (Travis 
et al 2006). 
4.1.2 Mesalamine, sulfasalazine, and antibiotics 
According to one meta-analysis, the benefit of 5-aminosalicylic acid (5-ASA) mesalamine 
in induction and maintenance of CD remission is limited (Hanauer and Stromberg 2004). 
However, it may prove of some benefit in the postoperative treatment of small intestinal 
resection (Caprilli et al 2006). In mildly active colonic disease, especially when associated 
with arthropathy, sulfasalazine can be effective for induction of clinical remission, but its 
use is limited due to sulfa-related intolerance (Summers et al 1979). Some selected patients 
with colonic disease can response to metronidazole, but it is not considered first-line 
therapy (Sutherland et al 1991). When combined with azathioprine, metronidazole may be 
useful in selected patients in prevention of postoperative recurrence (D´Haens et al 2008a). 
Antibiotics are in general considered appropriate in septic complications, in perineal 
disease, or in symptoms due to bacterial overgrowth (Travis et al 2006). 
4.1.3 Immunomodulators 
Immunomodulators should be started in corticosteroid-dependent or corticosteroid-
refractory disease or in extensive small bowel CD (Travis et al 2006). Thiopurines 
(azathioprine and 6-mercaptopurine) and methotrexate are immunomodulatory 
medications. A Cochrane analysis has shown the benefit of thiopurines compared with 
placebo in inducing remission in active CD (Sandborn et al 1998). Azathioprine has 
proven efficacious in the maintenance of remission in an analysis reviewing five clinical 
trials (Pearson et al 1998). As the onset of action is delayed, thiopurines are suitable for 
CD maintenance treatment, but not for a rapid induction of remission. In both ileal and 
colonic CD, azathioprine therapy can lead to mucosal healing (D'Haens et al 1997, 1999a). 
Methotrexate has been less studied than azathioprine, but mucosal healing seems to occur 
during intramuscular methotrexate therapy (Kozarek et al 1989). In placebo-controlled 
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trials, methotrexate showed effectiveness in both inducing and in maintaining CD clinical 
remission (Feagan et al 1995, 2000). 
4.1.4 TNFα-blocking agents 
Infliximab is an intravenously adminstered chimeric immunoglobulin G1 monoclonal 
antibody against TNFα that has been shown to induce both rapid clinical remission and 
endoscopic healing in CD (D'Haens et al 1999b, Travis et al 2006). By 10 weeks, repeated 
infliximab infusions (0, 2, and 6 weeks) resulted in complete mucosal healing more often 
(29% versus 3%) than did only one baseline infusion (Rutgeerts et al 2004). At one year, 
systematic treatment (scheduled infusions every 8 weeks) has been superior to episodic 
treatment in inducing clinical remission (Hanauer et al 2002) and complete mucosal 
healing (Rutgeerts et al 2004). It seems that mucosal healing is associated with fewer 
hospitalizations and surgeries, but the data are as yet limited (Rutgeerts et al 2004). In 
recently diagnosed CD patients, early treatment with combined immunosupression 
(infliximab and azathioprine or methotrexate) seems to be more effective than conventional 
management for induction of remission or reduction of corticosteroids through 52 weeks 
(D’Haens et al 2008b). Infliximab is indicated in moderate to severe corticosteroid-
refractory or -dependent, or in immunomodulator-refractory disease or intolerance (Travis 
et al 2006). It is also effective in the induction and maintenance of perianal or abdominal 
fistulating CD (Sands et al 2004).  
Adalimumab is a fully human anti-TNFα monoclonal antibody administered by 
subcutaneous injections usually every other week. Adalimumab has been effective in 
inducing clinical remission in both TNF-naïve patients and in those patients who have lost 
response or are intolerant to infliximab (Hanauer et al 2006, Sandborn et al 2007a). 
Through week 56, adalimumab has been superior to placebo in maintaining remission in 
initial responders (Colombel et al 2007). Data on mucosal healing during adalimumab 
treatment are, however, as yet limited.  
Certolizumab, a pegylated humanized TNFα-binding Fab´fragment, is administered 
subcutaneously. In a placebo-controlled trial, it showed only a modest response in 
moderate to severe CD and led to non-significant improvement in remission rates 
(Sandborn et al 2007b). Patients who responded to induction therapy with certolizumab 
were more likely to maintain the response and sustain remission at 26 weeks with 
continous certolizumab than did those switched to placebo (Schreiber et al 2007). 
Under research are several biological therapies targeted to mechanisms other than 
blockade of TNF, including modulation of other cytokines, blockade of T cells, and 
blockade of inflammatory cell migration and adhesion. The blockade of α4-integrin with 
natalizumab showed promising results in treatment of CD, but it is not available in Europe 
because of reported severe adverse effects (Baumgart and Sandborn 2007). 
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4.2 Operative treatment  
Although surgery in CD is limited to complications of CD such as strictures and fistulas, it 
is often needed as part of the treatment. In a cohort of 592 CD patients diagnosed from 
1966 to 1969 and observed for at least 7 years, 225 (91%) ileocolonic CD patients, 108 
(65%) with small bowel disease, and 105 (58%) with colonic or anoperineal disease 
underwent a surgical procedure (Farmer et al 1985). According to Loftus et al (2002), 40 
to 60% of  CD patients need at least one operative procedure. During a 5-year follow-up in 
Norway, 28% of CD patients underwent surgery with intestinal resection, and half of these 
had disease limited to the terminal ileum (Henriksen et al 2007). According to a 
retrospective trial, need for surgery has not decreased significantly over the last 25 years, 
although immunosuppressant use has been more frequent (Cosnes et al 2005).  In northern 
Europe, CD patients seem more likely to be treated with surgery than in southern Europe 
suggesting a disease-severity gradient across Europe (Wolters et al 2007).  
     Specific indications for surgery include symptomatic fibrostenotic strictures, 
enterovesical or enterocutaneous fistulas, and enteral fistulas leading to abscesses (Larson 
et al 2004). Perforation of the bowel or severe bleeding may necessitate surgical treatment.  
Perianal or rectovaginal fistulas often need a combination of surgical and medical 
treatment. Small bowel resection should be as bowel-sparing as possible. Strictureplasty 
can be performed on isolated strictures under 10 cm in length. Symptomatic relief is 
achieved in the majority of patients, with second surgery rates of between 34 and 44% 
during a 7-year follow-up (Larson et al 2004).   
4.3 Nutritional therapy 
Nutritional support is often required in severe CD for treatment of malnutrition. Enteral 
feeding has been effective in CD, but it requires high patient motivation, can be 
unpalatable, and is costly. In adolescents refractory or intolerant to corticosteroid therapy 
and with growth failure it may become the treatment of choice (King et al 1997). In one 
recent study, a long-term enteral nutrition in quiescent CD seemed to result in a 
suppressive effect on clinical and endoscopic disease activity and on mucosal cytokine 
levels (Yamamoto et al 2007).  
5 Assessment of disease activity  
5.1 Clinical activity   
Various activity indices have been developed to standardize and quantify disease severity. 
In clinical trials, the score most commonly used is the Crohn’s disease activity index 
(CDAI) which comprises eight clinical variables (Table 1) (Best et al 1976). CDAI scores 
range from 0 to approximately 650. A CDAI <150 has been the limit for clinically inactive 
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disease, and for severe disease the cutoff value has been 450. Furthermore, some 
investigators have arbitrarily labeled CDAI scores of 150 to 219 as mildly, and 220 to 450 
as moderately active disease (Sostegni et al 2003). Clincal response is suggested to be 
defined as ΔCDAI ≥-100 points, although some clinical trials have used ΔCDAI ≥-70 for 
response (Stange et al 2006).  
The CDAI score is not actively used in everyday clinical work because of its rather 
complex calculation and the need for a 7-day diary of symptoms. Further, it is not useful in 
patients with extensive previous ileocolonic resection or stoma and it is not accurate in 
patients having symptoms mainly due to fistulating and stenosing behavior. A limitation of 
the CDAI score is also a relevant weight for scores of “general well-being” and “intensity 
of abdominal pain” items, which are subjective and reflect patients’ perceptions of their 
disease (Sostegni et al 2003). For scoring of clinical disease activity of children, a pediatric 
Crohn’s disease activity index (PCDAI) has been developed (Hyams et al 1991). 
 
 
Table 1. Crohn´s Disease Activity Index (CDAI) (Best et al 1976). 
 
 
 
A summary of different clinical activity indices is presented in Table 2.  A simple index 
or Harvey Bradshaw index (HBI) is often used in clinical trials; it is based on five variables 
(Harvey and Bradshaw 1980) and correlates closely with the CDAI. Clinical remission is 
usually assessed as a HBI less than four or five (Tibble et al 2000a, Kane et al 2003). A 
modification of HBI is suggested to limit the effect of bowel movement number on total 
score (by scoring this variable on a scale from 0 to 5) (Myren et al 1984).  A meeting of the 
International Organisation for the Study of Inflammatory Bowel Disease in Oxford 
proposed an index based on nine clinical and one hematological parameter (Myren et al 
Variable  Description  Multiplier 
Number of liquid 
stools 
sum of 7-day numbers x2 
Abdominal pain sum of 7-day scores, ratings from 0 to 3 
(none =0, mild =1, moderate =2, severe =3)  
 
x5 
General well-being sum of 7-day scores, ratings from 0 to 4 
(generally well =0, slightly poor =1, poor =2, very    
poor =3, terrible =4) 
x7 
Extraintestinal 
complications  
number of listed complications 
(arthritis/arthralgia, iritis/uveitis, erythema nodosum, 
pyoderma gangrenosum, aphtous stomatitis, anal 
fissure/fistula/abscess, fever >37.8°C) 
x20 
Antidiarrheal drugs use in the previous 7 days (no =0, yes =1) x30 
Abdominal mass no =0, questionable =2, definite =5 x10 
Hematocrit (Hct) females 42-observed Hct; males 47-observed Hct x6 
Body weight ideal/observed ratio [1-(ideal/observed)] x 100 x1 (not < -10) 
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1984).   The Cape Town index, also proposed for assessment of clinical activity, and the 
Oxford index correlate with the CDAI (Myren et al 1984, Wright et al 1985, Sostegni et al 
2003), whereas the prospectively validated van Hees or Dutch index—a combined clinical 
and laboratory index—correlates poorly with the CDAI (van Hees et al 1980, Sostegni et 
al 2003). Compared to the HBI and van Hees indices, the CDAI has the highest variation, 
and self-reported wellness contributed 40% to total variance in the CDAI (Jorgensen et al 
2005). 
The CDAI in fistulating CD represents poorly the activity of perianal disease or CD 
with other fistulas. The perianal disease activity index (PDAI) represents at present the 
gold standard for evaluating perianal disease severity (Sostegni et al 2003).  
 
 
Table 2. Various clinical activity indices for Crohn’s disease. 
 
Activity index reference variables 
CDAI  Best et al 1976 diarrhea, abdominal pain, general well-being, 
extraintestinal  manifestations, use of 
antidiarrheal medications, presence of 
abdominal mass, hematocrit, weight  
 
HBI 
 
Harvey and Bradshaw 1980 
 
number of liquid stools, abdominal pain, 
general well-being,  extraintestinal 
manifestations, abdominal mass 
 
van Hees index 
(Dutch index) 
 
van Hees et al 1980 
 
serum albumin, ESR, Quetelet index (weight 
x 10/height x height), abdominal mass, 
gender, temperature, stool consistency, 
previous resection, extraintestinal lesions 
 
Oxford index 
 
 
Myren et al 1984 
 
pain, bowel action or blood and mucus, 
perianal complications, fistula, other 
complications, abdominal mass or tenderness, 
wasting, temperature, hemoglobin  
 
Cape Town index  
 
 
 
 
PCDAI 
 
 
 
 
 
PDAI 
 
 
 
Wright et al 1985 
 
 
 
 
Hyams et al 1991 
 
 
 
 
 
Irvine 1995 
 
 
abdominal pain, diarrhea or blood and mucus,  
well-being, complications (perianal or 
systemic),  abdominal mass and tenderness,  
weight, temperature, hemoglobin 
 
abdominal pain, diarrhea,  general well-being, 
weight and height, abdominal findings 
(tenderness and mass), perirectal disease, 
extraintestinal manifestations, hematocrit, 
ESR, s-albumin 
 
discharge of fistulas, pain/restriction of 
activities, restriction of sexual activity, type of 
perianal disease, degree of induration 
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CDAI, Crohn’s disease activity index, HBI, Harvey-Bradshaw index; ESR, erythrocyte 
sedimentation rate; PCDAI, pediatric Crohn’s disease activity index; PDAI, perianal 
disease activity index. 
5.2 Endoscopic activity   
Endoscopy with biopsies is the current gold standard for assessing intestinal inflammation. 
In addition to diagnostics, clear-cut indications for endoscopy are assessment of the disease 
activity and extension, dilation of strictures, and surveillance of long-standing chronic 
colonic disease (Hommes and van Deventer 2004).  
     Follow-up endoscopies are needed when uncertainty exists about disease activity or 
disease location. The location of inflammation is relevant for the choice of treatment 
(systemic or topically active). In CD, blood tests and symptoms do not necessary correlate 
accurately with endoscopic disease activity (Cellier et al 1994). When activity is measured 
by fecal excretion of 111In-labeled granulocytes, intestinal inflammation is often present in 
symptomless patients (Saverymutty 1986). On the other hand, symptoms compatible with 
irritable bowel syndrome (IBS) can sometimes dominate the clinical picture despite IBD 
remission and can be two to three times as prevalent in IBD as in the non-IBD population 
(Simren et al 2002).  
      Assessment of mucosal healing during therapy is relevant for clinical practice and also 
for response evaluation during clinical trials (Hommes and van Deventer 2004, Rutgeerts 
et al 2007). For treatment of IBD, recent studies and reviews suggest mucosal healing as a 
therapeutic target (Arnott et al 2002, Froslie et al 2007). Total disappearance of mucosal 
ulcerations has served in infliximab trials as the definition of complete mucosal healing 
(Rutgeerts et al 2004, 2006), but the significance of subtle changes (for example an 
aphthous ulcer) in otherwise healed mucosa remains unknown. The optimal timing for 
detection of mucosal healing remains undetermined (Rutgeerts et al 2007). Furthermore, 
endoscopy fails to detect disease activity beyond the mucosa. For detection of transmural 
disease activity, the imaging techniques, decribed in section 3.3 may be useful.  
5.2.1 Crohn’s disease index of severity (CDEIS) 
To measure endoscopic disease activity of CD, the French group GETAID (Groupe 
d´Etude Therapeutique des Afflections Inflammatoires Digestive) developed the Crohn’s 
disease index of severity (CDEIS) (Mary et al 1989). At present it represents the gold 
standard for evaluation of endoscopic CD activity (Table 3) (Sostegni et al 2003). For 
calculation of the CDEIS, the intestine is divided into five segments: rectum, left colon and 
the sigmoid, transverse, and right colon, and the ileum; nine mucosal lesions are recorded 
from each studied segment: pseudopolyp, healed ulceration, frank erythema (plaques, 
bands, or diffuse), frankly swollen mucosa, aphthoid ulceration, superficial or shallow 
ulceration, deep ulceration, non-ulcerated stenosis, and ulcerated stenosis. The percentage 
of the segmental surfaces involving the disease and ulcerations are positioned on a 10-cm 
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analogue scale between 0 and 10 (no lesion=0, lesions or ulcerations involving 100% of the 
segment =10).  For the ileum and for colonic segments only partially explored, the 10-cm 
scale represented the area actually seen (Mary et al 1989). The CDEIS can potentially 
range between 0 and 44, with higher scores reflecting greater endoscopic activity. The 
CDEIS correlates poorly with clinical activity (Modigliani et al 1990, Cellier et al 1994). It 
is fairly time-consuming, and elaboration of the score requires analogue scale 
transformation, making the CDEIS unsuitable for everyday clinical practice. 
 
 
Table 3. Scoring system for Crohn’s disease index of severity (CDEIS) (Mary et al 1989). 
 
 
5.2.2  Simple endoscopic score for Crohn’s disease (SES-CD) 
To simplify endoscopic assessment, a simple endoscopic score for Crohn’s disease (SES-
CD) has been developed and validated (Daperno et al 2004). It correlates closely with the 
CDEIS and is easier and faster to score and calculate. The SES-CD is based on four 
variables scored in the same five ileocolonic segments as in the CDEIS (Table 4). The 
ileum is scored for the full extent to which it is examined. The ileal score excludes the 
ileocecal valve or ileocolonic anastomosis. The right colon includes the ileocecal valve, the 
cecum, and the ascending colon up to the hepatic flexure. The transverse colon is defined 
as the segment between the hepatic and splenic flexures. The left colon includes the 
descending colon and sigmoid. The rectum is defined as the portion distal to the 
  total 
Deep ulcerations  
(if present, score =12) 
ileum, right colon, transverse colon,  sigmoid 
and left colon, rectum 
total 1 
 
 
Superficial ulcerations  
(if present, score =6) 
ileum, right colon, transverse colon,  sigmoid 
and left colon, rectum 
 
     total 2 
Surface affected 
by disease (cm) 
ileum, right colon, transverse colon,  sigmoid 
and left colon, rectum 
total 3 
 
Surface affected 
by ulcerations (cm) 
 
ileum, right colon, transverse colon,  sigmoid 
and left colon, rectum 
 
total 4 
   
                                                    total 1+2+3+4= total A 
 number of segments totally or partially explored n 
                                                    total A/n= total B 
 if a non-ulcerated stenosis present, add 3= C 
 if an ulcerated stenosis present, add 3=       D 
                                                    total B+C+D=       CDEIS 
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rectosigmoid junction. The score can range from 0 to 60. In the validation study, 
correlations of the SES-CD with serum CRP and the CDAI were significant (Daperno et al 
2004). A modification of this score ranging from 0 to 15 served for a subgroup of patients 
in a “topdown” therapy study showing at week 104 a significantly lower endoscopic score 
in patients with early combined therapy than in those receiving conventional treatment 
(D’Haens et al 2008b). 
 
 
Table 4. Definitions of the simple endoscopic score for Crohn’s disease (SES-CD) 
(Daperno et al 2004). 
 
Variable  
 
Score =0 
 
Score =1              
 
Score =2 
 
Score =3 
size of ulcers       none    aphthous ulcers 
(diameter: 0.1 to 
0.5 cm) 
large ulcers  
(diameter:  0.5 to 
2 cm) 
ulcers >2cm 
 
ulcerated 
surface  
 
affected 
surface  
      
     none 
 
 
     unaffected 
 
<10% 
 
 
<50% 
 
10-30% 
 
 
50-75% 
 
>30% 
 
 
>75% 
 
presence of 
narrowings   
       
      none  
 
single,  
can be passed 
 
multiple, 
can be passed 
 
cannot be passed 
     
5.2.3 Rutgeerts’ score 
After a curative resection of CD, endoscopic examination reveals signs of endoscopic 
activity in up to 60 to 70% of patients at 6 to 12 months, and severity of the lesions 
predicts subsequent clinical course (Rutgeerts et al 1984, 1990). For scoring of the disease 
in the ileum, Rutgeerts and coworkers (1990) have developed a score considered the gold 
standard for endoscopical post-surgical recurrence evaluation (Sostegni et al 2003).  
Findings in the ileum are scored in five categories: i0 is scored when no lesions occur in 
the distal ileum, i1 means  ≤5 aphthous lesions, i2 means >5 aphthous lesions with normal 
mucosa between the lesions, or skip areas of larger lesions or lesions restricted to 
ileocolonic anastomosis, i3 represents aphthous ileitis with diffusely inflamed mucosa, and 
i4 means diffuse inflammation with large ulcers, nodules, or narrowing (Rutgeerts et al 
1990).  
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5.3 Histologic activity 
Data available on the histology and activity of CD are limited, and among expert clinicians 
no general agreement exists as to the use of microscopy in assessment of CD activity 
(Stange et al 2006). Due to its uncertain clinical relevance, the histologic disease activity 
assessment cannot in general be recommended as a treatment endpoint (Sandborn et al  
2002). If biopsies are used, multiple samples are necessary for analysis. Several scoring 
systems for histologic findings exist. A scoring system for histologic findings demonstrates 
histologic healing in patients treated with azathioprine or infliximab (D’Haens et al 1997, 
1998, 1999b, Geboes et al 2005). Epithelial damage is classified as  normal (score =0), 
focal (score =1), or extensive (score =2) pathology; architectural changes as normal (score 
=0), moderately (<50%) disturbed (score =1), or severely (>50%) disturbed (score =2); 
infiltration of mononuclear cells in the lamina propria as a normal (score =0), moderate 
(score =1), or severe (score =2) increase; infiltration of polymorphonuclear cells in the 
lamina propria as normal (score =0), moderate (score =1), or severe (score =2) increase. 
Polymorphonuclear cells in the epithelium are scored 1 if in the surface epithelium, 2 if 
cryptitis is present, and 3 if a crypt abscess is present. When present, erosions or ulcers are 
scored as 1, and the presence of granuloma is scored as “yes” (score =1) or “no” (score 
=0). Finally, the number of biopsy specimens affected is scored none (score =0), <33% 
(score =1), 33% to 66% (score =2), or >66% (score =3). This scoring system is suggested 
for histologic CD findings in clinical trials (Sandborn et al 2002).  
5.4 Blood tests  
Peripheral blood inflammatory markers such as blood count, ESR, CRP, orosomucoid, and 
albumin have been routinely used for assessment of disease activity.  Also several other 
acute-phase proteins, many cytokines, and serological markers have been studied for 
detection of active disease.  These markers, however, reflect degree of inflammation in the 
whole body and are unable to detect sufficiently reliably inflammation in the GI tract. 
These tests thus cannot replace the need for clinical and endoscopic assessment of disease 
activity.   
5.4.1 Blood count 
In IBD, anemia, leukocytosis, and thrombocytosis are common findings. They are 
nonspecific, and the reason for anemia in CD can be multifactorial (iron deficiency due to 
blood loss, inflammation). An elevated leukocyte count may be an indicative of extensive 
active inflammation, but can also be a result of corticosteroid treatment. 
Immunosuppresive treatment may lower leukocyte count. Elevated platelet count is a 
nonspecific response to inflammation and may occur reactively during hemorrhage. It 
correlates weakly with clinical and endoscopic acitivity in CD (Cellier et al 1994). 
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5.4.2 Erythrocyte sedimentation rate 
ESR indirectly measures acute-phase plasma protein concentrations. It is influenced by 
erythrocyte morphology and number as well as by plasma components (for example, 
immunoglobulins). It is not rapidly responsive to changes in clinical status. In CD, ESR 
appears to rise with increasing activity in colonic disease, but fails to reflect disease 
activity of the small bowel (Sachar et al 1990, Desai et al 2007). 
5.4.3 C-reactive protein  
CRP is produced predominantly in the liver in response to stimulation by IL-6 and also by 
TNFα, and IL-1β (Florin et al 2006). In the presence of an acute-phase stimulus such as 
inflammation, production of CRP is rapidly upregulated.  The half-life of CRP is short (19 
hours) and thus, when the acute phase stimulus has disappeared, CRP concentration 
quickly falls (Desai et al 2007). In addition to active gut inflammation, elevated CRP can 
in CD be a sign of complications such as abscesses. Whereas CD is associated with a 
strong CRP response, the UC response is only modest or absent (Saverymuttu et al 1986a, 
Vermeire et al 2006). In diagnosis of CD, CRP is helpful, and its sensitivity values range 
between 70% and 100% depending also on the cutoff values used (Vermeire et al 2006). 
Lower sensitivity values have been reported by Tibble and coworkers (2002), who showed 
CRP (>5 mg/l) sensitivity (50%) and specificity (81%) in discriminating organic bowel 
disease from functional symptoms. In CD, elevated CRP is associated with clinically, 
endoscopically, and histologically active disease (Solem et al 2005).  During CD clinical 
remission, a persistently raised CRP may be associated with an earlier clinical relapse 
(Boirivant et al 1988). In clinically active CD, a low CRP value seems to be associated 
with ileal disease (Florin et al 2006).  
5.4.4 Orosomucoid 
The acute-phase reactant orosomucoid correlates with clinical disease activity, but its fairly 
long half-life (five days) makes it a less useful marker for clinical practice (Cellier et al 
1994, Vermeire et al 2006). 
5.4.5 Albumin 
In active IBD, serum albumin often declines and correlates inversely in CD with clinical 
and endoscopic activity (Modigliani et al 1990, Cellier et al 1994, Solem et al 2005). 
Hypoalbuminemia may be a consequence of protein loss from the inflamed gut or may 
result from malnutrition secondary to inadequate protein intake or malabsorption.  
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5.4.6 Cytokines 
TNFα is produced primarily by activated macrophages and monocytes. Although in active 
IBD serum TNFα is often increased, the serum concentrations are not consistently elevated 
and are thus of limited value as surrogate markers of IBD activity (Desai et al 2007).  
IL-6, a cytokine produced by macrophages and T cells, has both anti-inflammatory and 
proinflammatory properties. In CD, IL-6 is released in increased amounts from affected 
mucosa, and the level correlates with endoscopic findings (Reimund et al 1996). Serum IL-
6 concentrations correlate closely with the CDAI and are higher in those with 
inflammatory CD than in those with stricturing disease. Furthermore, during steroid-
treatment, serum IL-6 levels decrease in parallel with clinical improvement (Reinisch et al 
1999). 
In addition, several other serum cytokines and cytokine receptors such as IL-1β, IL-2, 
IL-2R, IFN-γ, IL-8, IL-23, IL-27, and IL-15 have been elevated in IBD, but these seem to 
have limited utility as non-invasive markers of disease activity, because serum levels often 
remain within normal limits despite active IBD (Desai et al 2007).  
5.4.7 Antibody responses to auto- and microbial antigens 
The serologic immune markers anti-Saccharomyces cerevisiae antibodies (ASCA) and the 
anti-neutrophil cytoplasmic antibody with a perinuclear staining pattern (pANCA) 
increasingly serve for IBD diagnosis. ASCA is directed to the phosphopeptidomannan wall 
component of the common baker’s yeast Saccharomyces cerevisiae. Elevated ASCA titers 
have been described in 50 to 80% of CD patients (in UC, 2 to 14%), whereas pANCA 
positivity is detectable in 40 to 80% of UC patients (Reese et al 2006, Papp et al 2007). 
These rarely appear in healthy controls. According to a meta-analysis comprising 4019 CD 
patients, a positive ASCA with a negative pANCA test gave a sensitivity of 55% and a 
specificity of 93% for CD. In pediatric patients, the sensitivity was somewhat better (70%, 
with a specificity of 93%) (Reese et al 2006). In CD, pANCA is often associated with UC-
like disease (Targan et al 2005). 
     Antibody responses toward Eschericia coli outer membrane porin C (anti-ompC), a CD-
related bacterial sequence from Pseudomonas fluorescens (anti-I2), and toward a flagellin 
CBir1 (anti-CBir1) are associated with CD in approximately 50% of patients. These 
markers are uncommon in UC or in a non-IBD population. Anti-I2 seems to associate with 
fibrostenosing small bowel CD and risk for small bowel surgery (Mow et al 2004). Anti-
ompC and anti-CBir1 are associated with small-bowel, fibrostenosis, and intestinal-
perforating disease features and anti-OmpC also with small bowel surgery (Mow et al 
2004, Targan et al 2005). Patients with a triple positivity for ASCA, anti-ompC, and anti-
I2 appear eight times more likely to require small bowel surgery than are seronegative 
patients (Mow et al 2004). These antibody responses may be helpful in subtyping Crohn’s 
disease patients and in prediction of disease course or in differentiation of colitis 
unclassified. In monitoring of CD activity these markers are of litte value: ASCA is fairly 
constant over time, and antibody responses to these microbial agents (ASCA, pANCA, 
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anti-I2, and anti-ompC) seem to remain unchanged in the majority of CD patients during 
anti-TNFα therapy (Landers et al 2002, Papp et al 2007).   
5.5 Radiolabeled neutrophils 
White cell scans with radiolabeled leukocytes or granulocytes can be useful in detecting 
acute inflammation. The technique of 111Indium-labeled granulocytes—rather than mixed 
leucocytes—has been modified for gastroenterological use. This technique involves 
abdominal scintigraphy and 4-day fecal collection of 111Indium-labeled granulocytes. Fecal 
excretion of 111Indium-labeled granulocytes has been considered a specific, quantitative, 
and sensitive measurement of intestinal inflammation (Saverymuttu  1985, Saverymuttu et 
al 1986b) and is suggested as the gold standard for assessing intestinal inflammation in CD 
(Gaya and Mackenzie 2002). In quiescent CD, this technique may reveal subclinical 
inflammation (Saverymuttu 1986). The main drawbacks of this procedure are a need for 
special labeling facilities, its cost, and a radiation burden. 
5.6 Intestinal permeability tests 
Intestinal permeability is assessed noninvasively by measuring urinary secretion of orally 
administered test substances. Permeability tests are non-specific for IBD. Usually two test 
substances based on different urinary excretion principles are combined, providing a 
specific index of intestinal permeability. The most often-used combination is a 
disaccharide (for example lactulose) and  a monosaccharide (L-rhamnose or mannitol). 
Many other substances used include 51Chromium-ethylene diaminetetraacetic acid (51Cr-
EDTA), 99Technetium-diethylene triaminepentaasectic acid (99Tc-DPTA), polyethylene 
glycol (PEG) (Bjarnason et al 1995), and even the water-soluble contrast medium iohexol 
(Halme et al 2000). Intestinal permeability tests are more suitable to assessment of small 
bowel disease activity than that of colonic CD. These are sensitive for detection of active 
small bowel CD and are considered useful tools for disease activity assessment (Bjarnason 
et al 1995). Lactulose-mannitol and iohexol tests have correlated with endoscopic and 
clinical CD activity (Halme et al 2000). In clinical CD remission, an abnormal 
permeability test seems to predict clinical relapse (Wyatt et al 1993, Tibble et al 2000b, 
Arnott et al 2000).  Fecal and gut lavage fluid calprotectin levels correlate with intestinal 
permeability tests in CD (Berstad et al 2000, Tibble et al 2002), and an abnormal 
calprotectin in combination with increased intestinal permeability gives an odds ratio of 
15.0 for small bowel disease (Tibble et al 2002). However, diagnostic accuracy in 
distinguishing between IBD and non-IBD conditions with an intestinal permeability test is 
inferior to use of fecal calprotectin (Canani et al 2006). 
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6 Calprotectin  
6.1 Structure and functions of calprotectin  
Called provisionally L1 or leukocyte-derived L1 protein, calprotectin was isolated from 
human granulocytes first by Fagerhol and coworkers (1980). It is a calcium- and zinc-
binding protein complex consisting of two heavy (14kDa) polypeptide chains and one light 
(8kDa) chain and has a molecular mass of 36.5 kDa (Dale et al 1983). The subunits of 
calprotectin have also been termed L1 light and heavy chains (Fagerhol et al 1980), 
migration inhibitory factor-related protein 8 (MRP8) and MRP14 (Odink et al 1987), 
calgranulin A and B (Wilkinson et al 1988), and S100A8 and S100A9 (Schafer et al 1995). 
The light chain is identical to the cystic fibrosis-associated antigen (CFAg) decribed in 
1973 (Wilson et al 1973). Calprotectin is a member of the S-100 protein family. 
Phagocytic S100 proteins are among damage-associated molecular pattern proteins 
(DAMPs) that are endogenous molecules released by activated or damaged cells under 
conditions of cell stress (Foell et al 2008). Genes coding for calprotectin are mapped to 
chromosome 1q21r (Schafer et al 1995). Calprotectin is a major component of human 
neutrophil granulocytes, constituting about 5% of their total protein and up to 60% of their 
cytosol protein (Fagerhol et al 1980, Dale et al 1985). Smaller amounts exist in the plasma 
membrane and nucleus. Calprotectin is also expressed in activated macrophages and 
monocytes, but is undetectable in lymphocytes (Dale et al 1985, Johne et al 1997).  
     The biological functions of calprotectin are not fully known. Upon neutrophil activation 
or upon endothelial adhesion of monocytes, calprotectin is released and is detectable in 
serum, body fluids, and feces. DAMPs promote inflammation through activation of PRRs: 
Calprotectin activates macrophages via interaction with TLR4 (Vogl et al 2007). 
Antimicrobial and fungistatic properties are mediated through the zinc-binding capacity of 
calprotectin (Steinbakk et al 1990). Calprotectin can inhibit zinc-dependent matrix 
metalloproteinases needed in many biological functions such as in wound healing, 
inflammation, angiogenesis, and tissue destruction (Střiž et al 2004). Calprotectin has also 
apoptosis-inducing properties, immunoregulatory functions, and cytotoxic and growth-
inhibitory effects (Yui et al 1997, 2003, Johne et al 1997, Mikami et al 1998). Excessive 
concentrations of calprotectin may induce cell and tissue damage (Yui et al 2003).   
6.2 Plasma calprotectin 
Calprotectin can be measured in plasma (Berntzen et al 1991), synovial fluid (Berntzen et 
al 1991), saliva (Cuida et al 1995), cerebrospinal fluid (Dunlop et al 1991), and urine (Holt 
et al 1983). It is absent from healthy skin, but is expressed in various inflammatory 
dermatoses (Brandtzaeg et al 1992). Plasma calprotectin levels are about 30% higher in 
men than in women (Dale 1990). Its serum or plasma levels are increased in many diseases 
in which neutrophils are recruited, diseases such as  rheumatoid arthritis (Berntzen et al 
1991), polymyalgia rheumatica (Brun et al 2005, Korndorfer et al 2007), cystic fibrosis 
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(Golden et al 1996), chronic bronchitis (Stockley et al 1984, Roth et al 1992), acute 
allograft rejection (Burkhardt et al 2001), gut inflammation (Leach et al 2007), alcohol-
induced liver cirrhosis (Homann et al 1995), acute pancreatitis (Carroccio et al 2006), 
preeclampsia (Braekke et al 2005), some malignant diseases (Kristinsson et al 1998, 
Odegaard et al 2008), and active multiple sclerosis (Bogumil et al 1998). In severe 
bacterial infections, plasma calprotectin levels may increase to 40- to 130-fold, whereas in 
viral infections, concentration may be normal or only slightly elevated (Sander et al 1984).  
6.3 Fecal calprotectin 
6.3.1 Fecal calprotectin assay 
Using polyclonal rabbit calprotectin antibodies, Roseth and coworkers (1992) developed a 
method for extraction of calprotectin from feces and quantification by an enzyme-linked 
immunoassay (ELISA). In 33 healthy volunteers, the median fecal calprotectin was 2 mg/l 
(milligram calprotectin per liter of fecal homogenate) and in the non-IBD control group 10 
mg/l, both of which were significantly lower than the fecal calprotectin concentrations in 
their CD patients (n=21, 43 mg/l) or in UC patients (n=17, 40 mg/l) (Roseth et al 1992). In 
the presence of Ca2+, calprotectin is resistant to degradation and at room temperature stable 
in stool for up to seven days (Roseth et al 1992). This makes possible transport of samples 
to the laboratory by ordinary mail. Fecal calprotectin levels in healthy individuals are 
approximately six times as high as in plasma (Angriman et al 2007).  
     An improved immunoassay for fecal calprotectin was published in 2000 (Ton et al 
2000). The increased calprotectin yield with this method resulted from dissociating agents 
in the extraction solution and an increased ratio between extraction solution and feces. 
Compared to the older method, the separation between normal and pathological values is 
better with the improved method and an approximately five-fold increase in fecal 
calprotectin concentration occurs. Both the average daily fecal calprotectin excretion and 
the calprotectin concentration of a single spot-sample correlate closely with fecal 
111Indium-labelled granulocyte excretion (Roseth et al 1999, Tibble et al 2000a). Need for  
only 50 to 100 mg feces in the new method, compared to 5 g in the original method, makes 
sample collection more convenient for the patient. The normal level of fecal calprotectin is 
suggested to be <50 μg/g. However, using meta-analytical techniques, von Roon et al 
(2007) found higher precision at a cutoff of 100 μg/g in distinguishing IBD from non-IBD 
conditions. In inflammation, calprotectin concentration in feces can rise as high as to tens 
of thousands μg/g (Fagerhol 2000). The concentrations measured with the older assay can 
be converted to the newer assay by multiplying them by five (Ton et al 2000). A 
polyclonal calprotectin ELISA test is commercially available (PhiCal Test®, Calpro AS, 
Oslo, Norway and Calprest®, Eurospital, Trieste, Italy). Furthermore, a monoclonal 
calprotectin test is available (Bühlmann Laboratories AG, Schönenbuch, Switzerland) and 
an assay using two selected monoclonal antibodies (Immundiagnostik  AG, Bensheim, 
Germany) is used in some studies (Langhorst et al 2005, 2008, Schröder et al 2007).  
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Recently, rapid semi-quantitative tests have been developed and validated for 
identifying patients with GI inflammation (Damms et al 2008, Vestergaard et al 2008, 
Otten et al 2008). A quantitative ELISA test seems, however, to be more suitable for 
monitoring of IBD activity than these rapid tests.  
6.3.2 Fecal calprotectin excretion 
Calprotectin excretion may reflect increased neutrophil and mononuclear cell migration 
into the gut lumen through the inflamed mucosa (Roseth et al 1999). Fecal calprotectin is 
specific for inflammation, but not disease-specific, as it may, besides IBD, be elevated also 
in inflammatory conditions such as enteropathy caused by non-steroidal anti-inflammatory 
drugs (NSAIDs) (Tibble et al 1999), in gastrointestinal neoplasms (Roseth et al 1993, 
Kristinsson et al 1998, Tibble et al 2001, Johne et al 2001, Hoff et al 2004), 
gastrointestinal infections (Hoff et al 2004, Kristinsson et al 1998), necrotising 
enterocolitis (Carroll et al 2003), food allergies (Carrocio et al 2003), acute radiation-
induced proctitis (Larsen et al 2004,  Hille et al 2008), and intestinal allograft rejection 
(Sudan et al 2007). Calprotectin concentrations may also be elevated in subjects with 
microscopic colitis (Limburg et al 2000) and in patients with pouchitis (Thomas et al 
2000). In untreated celiac disease, in which the mucosal inflammation is typically 
lymphocyte-predominant, the fecal calprotectin concentration does not necessary differ 
from that of controls (Montalto et al 2007a). Furthermore, in patients with liver cirrhosis, 
fecal calprotectin can be falsely positive, possibly due to mucosal abnormalities in patients 
with portal hypertension (Carrocio et al 2003). 
     Fecal calprotectin is already present in meconium even at low gestational ages (Laforgia 
et al 2003), and it is—apparently as a normal phenomenon— higher (>10-fold) in infants 
in the first year of life than in children over one year (Olafsdottir et al 2002,  Campeotto et 
al 2004). From that age up to 17-year-old healthy children, median calprotectin 
concentration seems to be similar to that of healthy adults (Carroccio et al 2003, Fagerberg 
et al 2003, Baldassarre et al 2007). Interestingly, in adults, stool calprotectin seems to 
increase with age and has a significant positive relationship to obesity and physical 
inactivity and an inverse relationship to fiber intake and vegetable consumption—all of 
these lifestyle factors being associated with colorectal cancer (Poullis et al 2004). Probably 
representing subclinical inflammation, elevated calprotectin concentrations occur in 
relatives of CD and UC patients and also in relatives of ankylosing spondylitis patients 
(Thjodleifsson et al 2003, Bjarnason et al 2003, Montalto et al 2007b). 
     A day-to-day variation in calprotectin excretion during three consecutive days has been 
demonstrated both in IBD patients and in controls (Roseth et al 1999). A similar biological 
day-to-day variation in fecal calprotectin among 14 patients scheduled for colonoscopy 
without colonic neoplasm or inflammation has occurred in 64% of patients, whereas values 
were noticeably stable in the remaining 36% (Husebye et al 2001). A high number of 
replicates (n=8) revealed this feature, and 20% of the measurements exceeded 50 μg/g. The 
reason for this bimodal pattern of calprotectin excretion is unknown, but it must be 
considered in any interpretation of a sole stool test in clinical practice (Husebye et al 
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2001). Preparation of the bowel for colonoscopy does not affect the stool calprotectin 
levels: In 17 patients, pre-and post-colonoscopy levels did not differ significantly 
(Summerton et al 2002). 
6.3.3 Fecal calprotectin for diagnosis of IBD 
The first studies showing the value of calprotectin in distinguishing organic intestinal 
disease from functional disorders were published in 2000. Tibble et al (2000a) studied 220 
consecutive adult patients with bowel symptoms suggestive of CD or IBS and found 
organic disease in 28%. Using a cutoff of 10 mg/l, the sensitivity and specificity of fecal 
calprotectin in discriminating between organic and functional intestinal disease was 82% 
and 83% (Tibble et al 2000a, Konikoff and Denson 2006). With a raised cutoff of 30 mg/l, 
the sensitivity was 100% and specificity 97% in distinguishing between active CD and IBS 
(Tibble et al 2000a, Gisbert and McNicholl 2008). Later, a larger study of Tibble’s group 
measured fecal calprotectin in 602 consecutive patients with abdominal symptoms (Tibble 
et al 2002). All patients provided stool samples for measurements of calprotectin, 
underwent an intestinal permeability test and radiological or endoscopic examinations for 
diagnosis; their symptoms were classified according to clinical criteria for IBS, Rome I 
criteria. Of these 602 patients, 263 (44%) had an organic bowel disease and 339 (56%) 
functional. At a fecal calprotectin cutoff level of 10 mg/l, the sensitivity was 89% and 
specificity was 79% for organic bowel disease. 
Limburg et al (2000) studied 110 adult patients referred for colonoscopy for chronic 
diarrhea or for chronic colitis of unknown activity. Increased calprotectin levels were 
significantly associated with colorectal inflammation, whereas fecal hemoglobin levels 
were not. At a cutoff level of 100 μg/g, the sensitivity for any colorectal inflammation was 
83% and the specificity 83%. The specificity rose to 90% when only those with 
histologically confirmed normal colorectal mucosa were considered, and when only IBD 
patients were considered, the sensitivity increased to 94% (Limburg et al 2000). In further 
studies, the sensitivity in adults has ranged from 63% to 100% and the specificity from 80 
to 100% in differentiating IBD from functional disorders. (Carroccio et al 2003, Costa et al 
2003, Dolwani et al 2004, Konikoff and Denson 2006, D'Inca et al 2007, Schoepfer et al 
2007, 2008, Kaiser et al 2007, Schröder et al 2007). Accordingly, positive predictive value 
(PPV) has been between 70 and 100% and negative predictive value (NPV) between 51 
and 91% (Carroccio et al 2003, Costa et al 2003, Konikoff and Denson 2006, D'Inca et al 
2007, Schoepfer et al 2007, 2008, Kaiser et al 2007, Schröder et al 2007).  
A meta-analysis based on prospective studies has evaluated the diagnostic precision of 
fecal calprotectin for IBD (von Roon et al 2007). A control group comprised patients with 
IBS or healthy controls. A total of 663 patients (both adults and children) had CD, 361 UC, 
and 183 patients were considered to have IBD. Fecal calprotectin concentrations in IBD 
patients were higher by 219 μg/g than in healthy controls. In CD patients, calprotectin 
levels were higher than in IBS patients by 304 μg/g. For diagnosis of IBD, a sensitivity of 
89% and a specificity of 81% was calculated from the data of nine studies (Tibble et al 
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2000a, 2001, Bunn et al 2001a, Summerton et al 2002, Fagerberg et al 2005, Bremner et al 
2005, Thjodleifsson et al 2003, Costa et al 2003, Carroccio et al 2003).  
Silberer et al (2005) studied fecal calprotectin, lactoferrin, polymorphonuclear 
neutrophil elastase (PMN-E), lysozyme, and alpha1-antitrypsin (α1-AT) in patients 
referred to colonoscopy and found PMN-E and calprotectin to be better than other markers 
in differentiation of IBD from IBS.  Compared to calprotectin, however, the granulocyte-
specific protein S100A12 seemed to show even better sensitivity and specificity in 
distinguishing active IBD from IBS (Kaiser et al 2007). 
For the diagnosis of IBD, fecal calprotectin appears to be superior to serological 
markers such as CRP, ESR, ANCA, or ASCA. In several studies, the sensitivity of CRP 
has ranged from 35 to 64% and the specificity 78 to 100% (Tibble et al 2000a, Canani et al 
2006, Silberer et al 2005, Fagerberg et al 2003, Schoepfer et al 2008). Accordingly, for 
ESR, sensitivity ranged from 18 to 52% and specificity from 78 to 100% (Tibble et al 
2000, Canani et al 2006, Silberer et al 2005, Fagerberg et al 2003). Overall diagnostic 
accuracy for CRP (65%) has been inferior to that of calprotectin (81%) or lactoferrin 
(77%) (Langhorst et al 2008). Furthermore, in predicting abnormal small bowel radiology, 
calprotectin seems to be more sensitive (100%) and specific (79%) than is a combination 
of elevated  CRP and ESR (sensitivity 50%, specificity 84%) (Dolwani et al 2004). In CD 
patients after ileocolonic resection, CRP correlated significantly with both fecal 
calprotectin and lactoferrin (r=0.53, p<0.01), but ESR correlated weakly only with 
calprotectin (r=0.28, p=0.03) (Scarpa et al 2007). 
In Schoepfer and coworkers’ study (2008) comparing calprotectin, lactoferrin, CRP, 
and serological CD markers (ASCA + and  pANCA + or -) in distinguishing CD from IBS, 
the sensitivity, specificity, PPV, and NPV of  CD markers were 63%, 96%, 95%, and 69%, 
while these values for calprotectin were 83%, 100%, 100%, and 83% and for lactoferrin 
83%, 96%, 96%, and 83%. Only marginal diagnostic accuracy resulted from combining 
calprotectin or lactoferrin with serological markers. In a recent Finnish pediatric study, 
however, combination of fecal calprotectin with ASCA, anti-I2, and with antibodies to 
Bacteroides caccae TonB-linked outer membrane protein (OmpW) resulted in a sensitivity 
of 100%, specificity of 36%, PPV of 66%, and NPV of 100% in detecting CD (Ashorn et 
al 2008). 
6.3.4 Fecal calprotectin and disease activity in CD 
Fecal calprotectin concentrations are elevated in both adults (Table 5) and children 
(Bremner et al 2005, Bunn et al 2001a, 2001b, Canani et al 2006, 2008) with IBD.  In CD, 
the CDAI is widely used as a measure of disease activity, but it correlates fairly weakly 
with fecal calprotectin (Costa et al 2003, Gaya et al 2005, Denis et al 2007, Scarpa et al 
2007). Calprotectin is often elevated also in clinical remission: in a study by Costa and 
coworkers (2003), patients with the CDAI >150 had a median calprotectin 405 μg/g 
whereas during clinical remission it was 213 μg/g. Furthermore, in one study of Tibble and 
coworkers (2000a), CD patients with clinically active disease (assessed with HBI) had a 
median calprotectin of 165 mg/l (converted to a newer assay, 825 μg/g) and in clinical 
 
 
 
 
38
remission 87 mg/l (newer assay: 435 μg/g). In children with HBI-assessed clinical 
remission, median fecal calprotectin was 1293 μg/g, whereas in clinically active disease it 
was 2557 μg/g (Walkiewicz et al 2008). In another study, patients in clinical remission (41 
of 49 patients with a CDAI ≤150) had an elevated calprotectin concentration 47 mg/l 
(converted to newer assay: 235 μg/g) (Thjodleifsson et al 2003). In 11 patients with a 
clinical relapse (CDAI >151) after an ileocolonic resection, median fecal calprotectin level 
was 233 μg/g, while in those 46 patients in clinical remission it was 217 μg/g (p=0.968) 
and correlation of the CDAI with calprotectin was nonsignificant (Pearson´s r=0.13, 
p=0.34) (Scarpa et al 2007). It seems that this relatively poor correlation of the CDAI with 
fecal calprotectin is due to the fact that CDAI is a clinical score and is insufficiently 
sensitive to detect intestinal inflammation. 
     A close correlation of the fecal 111Indium-labeled granulocyte-excretion—technique 
suggested as a gold standard for assessing intestinal inflammation (Gaya and Mackenzie 
2002)—with fecal calprotectin occurs in UC and CD (Roseth et al 1999, Tibble et al 
2000a). In 35 clinically active CD patients, calprotectin gave a sensitivity of 80%, a 
specificity of 67%, a PPV of 87%, and a NPV of 60% in detecting those CD patients who 
had inflammation in a white-cell scan (Gaya et al 2005). 
     Calprotectin correlates significantly with endoscopic and histologic activity in UC 
(Roseth et al 1997) and in pediatric IBD patients (Bunn et al 2001b), and its normal level 
in clinical IBD remission correlates closely with endoscopic mucosal healing both in 
children and in adults (Bunn et al 2001b, Roseth et al 2004, Fagerberg et al 2007). In CD, 
as well, significant correlations between fecal calprotectin concentrations and endoscopic 
disease activity have appeared (Silberer et al 2005, D'Inca et al 2007, Langhorst et al 2008, 
Schoepfer et al 2008), although these correlations may not be as apparent as in UC. In 
D’Inca and coworkers’ study (2007), endoscopic CD findings correlated with calprotectin, 
but not with histologic score. Lactoferrin, failed, however, to correlate with endoscopic 
score, but correlated with histology (D'Inca et al 2007). In Silberer et al’s study (2005), 
calprotectin and PMN-E were superior to lactoferrin, lysozyme, and α1-AT in detecting 
differences between endoscopically assessed IBD activity groups. When endoscopic 
inflammation in CD was present, calprotectin levels were elevated compared to findings 
with no inflammation (105 μg/g and 11 μg/g, p<0.01) (Langhorst et al 2008). Moreover, 
when the cutoff point SES-CD <20 was set  for endoscopically mildly  active CD, 
calprotectin was significantly higher in patients with moderately or severely active disease  
than in  those with mild disease (mean calprotectin ± standard deviation SD 433.0±42.6 
μg/g versus 112.1±31.3, p<0.001) (Schoepfer et al 2008). Interestingly, in Kaiser and 
coworkers’ study (2007), differences in calprotectin values between patients with active 
(median±95% confidence interval CI was 97±45 μg/g) and inactive IBD (19±158 μg/g) 
failed to reach statistical significance. In that study, IBD was considered inactive, when no 
signs of endoscopic and histologic inflammation were present and clinical activity scores 
were normal. 
 In children with inflammatory bowel disease (26 CD, 32 UC), fecal calprotectin has 
shown a good correlation with histologic grade of mucosal inflammation (r=0.655), and 
this correlation was similar to that observed for endoscopy (r=0.699) (Canani et al 2008). 
The sensitivity and specificity of fecal calprotectin in detecting histolocially active mucosal 
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inflammation was 94% and 64%. Accordingly, for endoscopy, the sensitivity as 67% and 
specificity was 82% (Canani et al 2008). 
No correlation appeared between the CDEIS and calprotectin or any other clinical or 
biological markers (ESR, acid α-1 glycoprotein, IL-6, IL-8, TNF-receptor type 2, and 
soluble IL-2R) in 28 CD patients with clinically active disease (CDAI >150) and normal 
CRP levels (Denis et al 2007).  
    Studies of calprotectin in monitoring treatment in CD are scarce. Following infliximab 
therapy, a transient decrease in fecal calprotectin concentrations in two CD patients 
corresponded to an improvement in clinical disease activity, but no endoscopic activity 
evaluation was performed (Aadland and Fagerhol 2002). In pediatric IBD patients during 
glucocorticoid therapy, fecal calprotectin decreased in line with clinical improvement, but 
seldom fell within the normal range–suggesting ongoing inflammation despite clinically 
quiescent disease (Kolho et al 2006). Exploration of repeated fecal calprotectin, lactoferrin, 
PMN-E, and lysozyme concentrations in 31 UC patients showed significantly higher 
calprotectin, lactoferrin, and PMN-E (but not lysozyme) values in the active disease than in 
the inactive disease phase (Langhorst et al 2005).   
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Table 5. Fecal calprotectin in adults with IBD. Modified from Konikoff MR, Denson LA. Inflamm 
Bowel Dis 2006;12:524-533. 
* Converted to newer assay. Median concentrations, if not mentioned otherwise. † mean 
concentration. IBS, irritable bowel syndrome; UC, ulcerative colitis; CD, Crohn’s disease; CAI, 
colitis activity index; CDAI, Crohn´s disese activity index; CDEIS, Crohn´s disease index of 
severity; SES-CD, simple endoscopic score for Crohn’s disease; ET, Edwards and Truelove score; 
HBI, Harvey Bradshaw index. § mildly active disease.  
reference patients 
n, 
disease 
assessment of  
activity 
calprotectin  
active 
disease,  
 μg/g 
calprotectin 
inactive 
disease,  
μg/g 
 
calprotectin  
controls or 
IBS 
μg/g 
Roseth et al 1992 
  
Roseth et al 1997 
21 CD 
17 UC 
62 UC 
clinical 
 
endoscopy 
histology 
218* 
98* 
325* 
340* 
- 
- 
70 *  
60* 
10* 
 
30* 
 
Roseth et al 1999 
 
Roseth et al 2004 
 
Limburg et al 2000 
19 CD 
10 UC 
17 CD 
28 UC 
16 UC 
or CD 
 
clinical remission 
clinical remission 
clinical and endoscopic  
(44/45)  remission 
endoscopy 
histology 
- 
- 
- 
- 
1722 
496* 
752* 
35 
16 
- 
 
58* 
 
- 
 
31 
 
Tibble et al  2000b 43 CD 
37 UC 
CDAI <150, HBI <4 
HBI <4 
- 
- 
475* 
290* 
- 
- 
Tibble et al 2000a 
Tibble et al 2000a 
 
Summerton et al  
2002 
Costa et al 2003 
 
Carrocio et al 2003 
Thjodleifsson et al  
2003 
Dolwani et al 2004 
Wassel et al 2004 
Costa et al 2005 
 
Langhorst et al 2005 
D’Inca et al 2007 
Denis et al 2007 
Schröder et al 2007 
 
Kaiser et al 2007 
 
Scarpa et al 2007 
Langhorst et al 2008 
 
Schoepfer et al 2008 
 
 
D’Inca et al 2008 
 
 
116 CD 
31 CD 
 
 4 CD 
10 UC 
49 CD 
82 UC 
10 CD 
49 CD 
 
25 CD 
25 CD 
38 CD 
41 UC 
31 UC 
46 UC 
28 CD 
25 CD 
20 UC 
59 UC 
or CD 
57 CD 
43 CD 
42 UC 
36 CD 
28 UC 
 
65 CD 
97 UC 
HBI cutoff 5 
symptoms,  
diagnostic procedures 
endoscopy 
 
CDAI cutoff 150 
UCAI cutoff 4 
CDAI >150 in 8/10 
CDAI ≤150 in 41/49 
 
CDAI >150 in 23/25 
CDAI >150 
CDAI <150 
UCAI <4 
CAI cutoff 5 
endoscopy 
CDEIS cutoff 6 
CDAI >150 
CAI ≥4 
endoscopic, 
histologic,clinical 
CDAI cutoff 150 
endoscopy 
 
endoscopy (SES-CD) 
endoscopy  
(Rachmilevitz score) 
CDAI <150 
ET <3 
 
825* 
675* 
 
164* 
267* 
405 
327 
320 
- 
 
227 
230 
- 
- 
57 
340 
77 
143 
137 
97 
 
233 
105 
109 
433† 
390† 
 
- 
- 
 
435* 
- 
 
- 
- 
213 
123 
- 
235* 
 
- 
- 
220 
151 
0.1 
161§ 
122 
- 
- 
19 
 
217 
11 
35 
112†§  
123†§  
 
99 
101 
 
10* 
10* 
 
23* 
 
22 
 
20 
20* 
 
10 
9 
 
- 
- 
- 
- 
6 
 
19 
 
- 
7 
 
19† 
 
 
- 
- 
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6.3.5 Fecal calprotectin in estimating CD relapse  
Typical for both CD and UC are mostly unpredictable activity relapses and longer or 
shorter remission periods. Preventive or early treatment would be possible, were an 
accurate marker for estimating relapse risk available. In IBD patients in clinical remission, 
Tibble et al (2000b) showed a single fecal calprotectin measurement to be a reliable tool in 
predicting clinical relapse within a year. At 50 mg/l (converted to newer assay: 250 μg/g), 
the sensitivity in all IBD patients was 90% and specificity was 83%. In that study, neither 
CRP nor ESR was useful in predicting relapse. Costa et al (2005), however, found fecal 
calprotectin to be more reliable for UC than for CD in estimating relapse of symptomless 
patients: In CD, the median calprotectin value in those who relapsed was 220 μg/g 
compared to 221 μg/g in non-relapsing patients (p=0.395), and the specificity was only 
43%, whereas in UC, median calprotectin in relapsing patients was 221 μg/g and in non-
relapsing patients 67 μg/g (p<0.0001). A fecal calprotectin concentration exceeding 150 
μg/g showed a 2-fold risk for relapse for CD and a 14-fold relapse risk for UC. Recently, 
fecal calprotectin proved to be useful in predicting relapse risk in UC, but in CD did so 
only for a subgroup of patients with colonic CD (D'Inca et al 2008). In children, fecal 
calprotectin level >400 μg/g seemed to predict relapse risk in a 9-month follow-up: 90% of 
relapsing CD patients had a calprotectin concentration over this limit (Walkiewicz et al 
2008). A retrospective analysis of pediatric IBD patients showed a calprotectin value of 
275 μg/g to have a sensitivity and NPV of 97% and a specificity and PPV of 85% in 
predicting histologic relapse (Diamanti et al 2008).  
 
7 Lactoferrin  
7.1 Structure and functions of lactoferrin 
Lactoferrin was first isolated from bovine milk almost 50 years ago (Groves 1960, 
Johanson 1960). The most striking characteristic of this 80-kDa glykoprotein was its 
intense red color when incubated in the presence of Fe2+ ions. The size and structure of 
lactoferrin is closely related to those of another group of iron-binding proteins, transferrins 
(Baker and Baker 2005, Levay and Viljoen 1995). Lactoferrin consists of a single 
polypeptide chain folded into two globular lobes, each having one iron-binding site (Ward 
et al 2002). Besides mammalian milk, lactoferrin is a component of many external 
secretions such as saliva, tears, semen, bile, and mucosal secretions (Baker and Baker 
2005, Levay and Viljoen 1995). Lactoferrin is present in relatively low concentrations in 
plasma and is predominantly neutrophil-derived. During pregnancy, lactoferrin levels in 
plasma rise. Plasma lactoferrin can be elevated in iron overload, in inflammation, 
infectious diseases, and during tumor development (Levay and Viljoen 1995).  
In polymorphonuclear neutrophils, lactoferrin is the major component of the secondary 
granules released by activated neutrophils during any inflammatory process. Monocytes 
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and lymphocytes produce no lactoferrin (Angriman et al 2007). Lactoferrin plays various 
roles in the body’s host defense and in iron metabolism by controlling iron availability. It 
also has both bacteriostatic and bacteriocidal properties and can affect the proliferation of 
other microbes such as fungi and viruses. It also plays a role in cellular proliferation 
(Levay and Viljoen 1995, Ward et al 2002).  
7.2 Fecal lactoferrin  
Fecal lactoferrin is less studied than is calprotectin. Fecal lactoferrin is stable and easy to 
detect and measure in stool by ELISA (Uchida et al 1994, Sugi et al 1996, Kayazawa et al 
2002). Also available is a qualitative latex agglutination test (Fine et al 1998, Schoepfer et 
al 2008) and a rapid immunocromatographic test (Otten et al 2008), but these are more 
suitable for noninvasive evaluation of organic bowel disease than for monitoring of disease 
activity in IBD. Like calprotectin, fecal lactoferrin is a nonspecific marker of intestinal 
inflammation: Besides in IBD (Sugi et al 1996, Kayazawa et al 2002), elevated 
concentrations have been detected in infective diarrhea (Guerrant et al 1992, Dai et al 
2007), in colon cancer (Uchida et al 1994), and in acute radiation-induced proctitis (Larsen 
et al 2004, Hille et al 2008). In pouchitis, too, lactoferrin levels and clinical disease activity 
correlate (Parsi et al 2004). 
An upper reference value of 2.4 μg/g has been suggested by Uchida et al (1994), 
whereas  the upper cutoff value of  the ELISA manufacturer is 7.25 μg/g (IBD-SCAN, 
Techlab, Blacksburg, VA, USA), and it is used in several studies (Langhorst et al 2005, 
2008, Schoepfer et al 2007, 2008).  
7.2.1 Fecal lactoferrin for diagnosis of IBD 
  In distinguishing IBD from IBS, the sensitivity of a quantitative fecal lactoferrin assay is, 
according to several studies, between 78 and 87% and its specificity between 85 and 100% 
(Kane et al 2003, Schoepfer et al 2007, 2008, D'Inca et al 2007, Schröder et al 2007). 
Accordingly, the PPV has been between 87% and 100% and NPV 77% and 81%  
(Schoepfer et al 2007, 2008, D'Inca et al 2007, Schröder et al 2007).  In 103 patients with 
diarrhea of unknown origin, the qualitative latex-agglutination test gave a sensitivity of 
90% and a specificity of 98% in detecting UC or CD (Fine et al 1998). In that study, of 
nine patients with microscopic colitis, eight had a negative lactoferrin test. 
7.2.2 Fecal lactoferrin and disease activity in CD 
Table 6 presents fecal lactoferrin concentrations in active and inactive IBD. Fecal 
lactoferrin levels are significantly higher in both clinically active UC and CD than in 
controls or in inactive disease (Sugi et al 1996, Kane et al 2003, Dai et al 2007). Levels are 
also significantly higher in endoscopically moderate or severely active CD than in mild 
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disease (Schoepfer et al 2007, 2008). When endoscopic inflammation in CD was present, 
lactoferrin level was significantly higher than in those with no inflammation (55.1 μg/g and 
6.4 μg/g, p<0.01) (Langhorst et al 2008) A significant difference also existed between 
endoscopically mildly active disease (SES-CD <20) and more active disease (mean 
lactoferrin±SD 37.9±11 μg/g versus 221.5±22.8 μg/g, p<0.0001) (Schoepfer et al 2008). 
Furthermore, in florid or mild endoscopic inflammation, lactoferrin was significantly 
higher than in healthy controls (p=0.0059) or in IBD remission (Silberer et al 2005). 
In a study by Scarpa and coworkers (2007), fecal lactoferrin failed to correlate with the 
CDAI in patients who had undergone a prior ileocolonic resection (Pearson´s r=0.24, 
p=0.07). Patients with diarrhea had significantly higher lactoferrin concentrations than did 
asymptomatic ones (median 25.5 μg/g versus 4.1 μg/g, p=0.003). This difference was not 
as evident with calprotectin (calprotectin in diarrhea patients 384.4 μg/g and in 
asymptomatic patients 263.9 μg/g, p=0.029).   
In five children with severe CD, fecal lactoferrin concentrations decreased quickly as a 
consequence of infliximab therapy (Buderus et al 2004). Moreover, in pediatric IBD 
patients being weaned from steroid therapy, fecal lactoferrin was higher than in clinically 
inactive disease, but lower than in patients with clinically active disease but receiving no 
steroids (Walker et al 2007). 
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Table 6.  Fecal lactoferrin levels in adult and pediatric IBD. 
 
 
† mean concentration. * measurements performed on whole-gut lavage fluid. 
Abbreviations as in Table 5. IBD, inflammatory bowel disease. § 52 samples of CD 
patients and 58 samples of UC patients. 
8 Other stool tests 
For detection of IBD activity, this section comprises the several other stool tests studied, 
which presents the fecal tests most often used. 
8.1 Alpha1-antirypsin 
Alpha1-antitrypsin is a protease inhibitor produced by the liver, macrophages, and 
intestinal epithelium. It is stable in feces and can be measured by commercially available 
assays.  It is suggested to represent fecal protein loss, but does not directly reflect intestinal 
inflammation (Sutherland et al 2008). In active CD, fecal α1-AT excretion is increased and 
reference patients 
n 
disease 
assessment of activity Lactoferrin 
in active 
disease 
μg/g 
Lactoferrin in 
 inactive 
disease 
μg/g 
Lactoferrin 
controls or 
IBS 
μg/g 
Uchida et al 
1994 
 
Kayazawa et 
al 2002* 
Kane et al 
2003 
Dai et al 
2007 
Schröder et 
al 2007           
Walker et al 
2007 
Scarpa et al 
2007 
Schoepfer et 
al 2008 
 
 
Langhorst et 
al 2008 
18 CD§ 
28 UC 
 
23 CD 
27 UC 
104 CD 
80 UC 
18 CD 
59 UC 
25 CD 
20 UC 
75 CD 
60 UC 
63 CD 
 
36 CD 
 
28 UC 
 
43 CD 
42 UC 
CDAI cutoff 150 
clinical and 
colonoscopy 
CDAI cutoff 150 
colonoscopy 
HBI cutoff 4 
HBI cutoff 4 
HBI cutoff 4 
HBI cutoff 4 
CDAI>150 
CAI≥4 
HBI cutoff 4 
HBI cutoff 4 
CDAI cutoff 150 
 
SES-CD cutoff 20 
 
Rachmilevitz score 
cutoff  4 
colonoscopy 
191.7† 
307.4† 
 
28.6† 
37.1† 
550† 
2020† 
1035.3† 
1126.3† 
45 
63 
2465† 
3121† 
8.3 
 
221.5† 
 
202.3† 
 
55.1 
51.1 
25.1† 
63.3† 
 
3.6† 
1.3† 
204† 
136† 
133.5† 
96.6† 
- 
- 
1055† 
79† 
5.5 
 
37.9 † (mildly 
active) 
124.8 † (mildly 
active) 
6.4 
4.3 
0.8† 
 
 
0.9† 
 
1.3† 
 
2.5† 
 
0.2 
 
1.2† 
 
- 
 
2.2† 
 
 
 
1.8 
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correlates with clinical activity (Roseth et al 1992, Sutherland et al 2008).  Fecal 
lactoferrin, which correlates significantly with α1-AT, detects CD patients with 
inflammation and normal α1-AT and seems to be a more suitable marker for clinical 
application than is α1-AT (Sugi et al 1996).  Sensitivity of α1-AT in distinguishing IBD 
from IBS is inferior to calprotectin, lactoferrin, PMN-E, myeloperoxidase (MPO), and 
lysozyme (Silberer et al 2005). However, based on a prospective study of 26 ileal CD 
patients, α1-AT may serve as an indicator of clinical relapse (Biancone et al 2003).  
8.2 Polymorphonuclear neutrophil elastase 
Polymorphonuclear neutrophil elastase is a neutral proteinase released from neutrophil 
azurophilic granules by activation. It can be measured as a complex with elastase bound to 
α-1-AT or as free fecal elastase (Sutherland et al 2008). Fecal PMN-E correlates closely 
with fecal lactoferrin, but its stability is inferior to that of lactoferrin (Uchida et al 1994, 
Sugi et al 1996). Compared to PMN-E, MPO, or lysozyme, lactoferrin seems to be a more 
suitable surrogate marker of inflammation (Sugi et al 1996, Kayazawa et al 2002). 
Furthermore, the sensitivity of PMN-E in distinguishing between IBD and IBS has been 
84% and specificity 87%, with values lower than those of calprotectin or lactoferrin 
(Schröder et al 2007). Silberer and coworkers (2005), found, however, that in 
distinguishing between IBD and IBS or healthy controls, PMN-E and calprotectin are more 
accurate than MPO, lysozyme, and lactoferrin. Furthermore, PMN-E and calprotectin 
correlate with the endoscopically classified severity of inflammation. A study of Langhorst 
and coworkers (2008) showed fecal PMN-E levels to be significantly higher in active than 
in inactive IBD, but calprotectin’s having the highest accuracy in CD. 
8.3 Myeloperoxidase 
Myeloperoxidase is another neutrophil product released from primary granules. Like 
lactoferrin, MPO is stable in whole-gut lavage fluid and correlates significantly with 
endoscopic findings in UC and with CD clinical activity (Kayazawa et al 2002). In Silberer 
and coworkers’ report (2005), MPO seemed to separate healthy controls and IBS patients 
from IBD patients less effectively than did PMN-E or calprotectin.  
8.4 Lysozyme 
Lysozyme, known also as muramidase, is a neutrophil-derived enzyme that mediates 
degradation of bacterial cell walls. It occurs both in azurophilic and in secondary 
neutrophil granules. The excretion of lysozyme is increased in IBD, particularly in colitis 
(Poullis et al 2002, Sutherland et al 2008). The stability of fecal lysozyme is inferior to that 
of calprotectin, lactoferrin, PMN-E, or MPO, making it less suitable for clinical use (Sugi 
et al 1996, Silberer et al 2005). 
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8.5 S100A12 protein 
Fecal S100A12-protein, known earlier as calgranulin C, is more restricted to granulocytes 
than is calprotectin and is abundant at sites of inflammation in the intestinal mucosa of IBD 
patients (Foell et al 2003, 2008).  It is secreted by activated neutrophils and promotes 
inflammation by binding to the receptor for advanced glycation endproducts (RAGE), 
leading to activation of NF-κB (Foell et al 2003). S100A12 is a non-specific marker of 
intestinal inflammation. Serum and mucosal levels of S100A12 are more elevated in IBD 
than in healthy controls (Leach et al 2007). According to a recent study, fecal S100A12 
correlates better with intestinal inflammation than does fecal calprotectin or other 
biomarkers (Kaiser et al 2007). In distinguishing active IBD from IBS, for calprotectin a 
sensitivity of 63% and a specificity of 86% appeared. Correspondingly, for S100A12, 
sensitivity was 86%, and specificity was 96% (Kaiser et al 2007). In distinguishing 
pediatric IBD- from non-IBD patients, both calprotectin and S100A12 gave a high 
sensitivity (of 100% and 97%), but the specificity of S100A12 was better (97% versus 
67%) (Sidler et al 2008).  
8.6 Eosinophil granule-derived proteins 
Fecal levels of eosinophil cationic protein and eosinophil protein X increase significantly 
in both active UC and clinically active CD (Saitoh et al 1999); in a 3-month follow-up, 
these proteins seem to predict relape in CD. 
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Aims of the study  
The aims of the present study were to 
 
1. study, in Crohn’s disease, the correlation of fecal calprotectin and lactoferrin 
concentrations with 
clinical and endoscopic  disease activity (Study I) 
 histologic disease activity (Study II). 
 
2.  explore, during Crohn’s disease anti-TNFα therapy, 
changes in fecal calprotectin and lactoferrin concentrations (Study III) 
parallel changes in mucosal effector and regulatory T-cell markers (Study IV). 
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Patients and methods  
1 Patients 
1.1 Cross-sectional Studies (I and II) 
1.1.1 Patients in Study I 
Between January 2005 and November 2006 in the Helsinki University Central Hospital 
clinic of gastroenterology, 84 adult CD patients referred for ileocolonoscopy were 
recruited. CD diagnosis was based on standard clinical, endoscopic, radiological, and 
histologic criteria. The Montreal classification served for CD classification (Silverberg et 
al 2005). Exclusion criteria were history of extensive bowel resection 
(ileosigmoideostomy, ileorectostomy), ostomy, long-term use of NSAIDs, pregnancy, or 
symptoms related mainly to perianal fistulating disease. Of the 84, five patients were 
excluded for failure to provide stool samples on time, one for positive fecal culture for 
Campylobacter jejuni, and one for canceling endoscopy.  
     The number of ileocolonoscopies was 106 for 77 patients (25 patients underwent 
endoscopy twice and two patients three times). Indications for endoscopy were assessment 
of endoscopic activity after medical treatment (n=35), clinically active disease (28), 
evaluation of endoscopic disease activity (20), stricture dilatation (9), postoperative 
evaluation (7), dysplasia surveillance for longstanding disease (7).  Each patient provided a 
single stool sample (during the week before bowel preparation or the week after 
endoscopy) and underwent blood sampling for blood count, albumin, ESR, and CRP. Stool 
samples were stored at -40ºC until analysis. The 13 patients who provided their stool 
samples outside the scheduled week (8 to 13 days before bowel preparation) remained 
included because of unchanged disease course. The CDAI served for assessment of clinical 
activity (Best et al 1976): CDAI <150 indicated clinically inactive, and scores 150 to 219 
mildly, 220 to 450 moderately, and >450 severely active disease (Sostegni et al 2003). 
Clinical characteristic of the patients are shown in Table 7. 
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Table 7. Clinical characteristics of the patients. 
GI, gastrointestinal. TNF, tumor necrosis factor. 
1.1.2 Patients in Study II 
We performed histology scoring for endoscopic findings of 67 patients who also 
participated in Study I. Two additional patients were included (a 52- and a 22-year-old 
woman). During the study period, 22 patients underwent ileocolonoscopy twice and two 
patients three times. Of 95 endoscopies performed, 8 remained incomplete due to a 
stricture or technical problems, and those were excluded. The overall number of 
 n  (%) 
Patients 77 
Gender, female/male 38/39 (49/51) 
Age, years, median  
Age at diagnosis, years 
<16 
17-40 
>40 
33.5 (range 19-70) 
 
5 (6) 
63 (82) 
9 (12) 
Disease location 
   ileum 
   colon 
   ileocolon 
   ileum + upper GI tract 
   colon + upper GI tract 
   ileocolon + upper GI tract 
 
19 (25) 
14 (18) 
37 (48) 
3 (4) 
0 
4 (5) 
Disease behavior 
   inflammatory 
   stricturing 
   penetrating 
   inflammatory + perianal disease 
   stricturing + perianal disease 
   penetrating + perianal disease 
 
28 (36) 
29 (38) 
7 (9) 
8 (10) 
4 (5) 
1 (1) 
Mean duration of disease, years 9.2 
Prior surgery: no/yes 44/33 (57/43) 
Smoking: no/yes 51/26 (66/34) 
Maintenance treatment/endoscopy 
   no medication 
   aminosalicylate or sulfasalazin 
   thiopurine or methotrexate 
   metronidazole 
   corticosteroids 
   TNFα antagonist 
 
 
12 (11) 
73 (69) 
72 (68) 
8 (8) 
12 (11) 
14 (13) 
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endoscopies analyzed in Study II was thus 87 performed on 61 patients. Findings of biopsy 
specimens were scored according to the histology score described below.  
 
1.2 Prospective treatment Studies (III, IV) 
1.2.1 Patients in Study III 
Between January 2005 and March 2007, adults with Crohn´s disease and scheduled for 
ileocolonoscopy were recruited. Of these 15 patients, 13 patients were included also in 
cross-sectional Study I. Based on global clinical assessment, these patients were considered 
to need anti-TNFα therapy, indications being an acute flare (n=6), chronic active disease 
(6), or rapid reoccurrence of the disease postoperatively (3). Exclusion criteria were contra-
indications for anti-TNFα treatment, pregnancy, ostomy, history of extensive bowel 
resection (ileosigmoideostomy, ileorectostomy), long-term use of NSAIDs, or perianal 
fistulating disease without luminal inflammation. 
Of 15 patients receiving anti-TNFα therapy, 6 were females. Median disease duration 
was 5.1 (range 0.4-27) years. Active ileal disease occurred in two, colonic disease in four, 
and ileocolonic disease in nine patients; CD behavior was inflammatory±perianal disease 
in ten and stricturing in five patients. 
Following the baseline endoscopy (median 7 days afterwards, range 1-38 days), anti-
TNFα therapy was introduced: One patient received adalimumab induction (80 mg 
followed by 40 mg subcutaneously every other week until week 8) and 14 patients received 
infliximab induction (intravenous infusion 5 mg/kg at weeks 0 and 8). Corticosteroids were 
tapered off after introduction of anti-TNFα treatment, but the maintenance therapy 
remained unchanged. At the time of the first ileocolonoscopy, and at 2, 8, and 12 weeks 
(10 weeks for the adalimumab-treated patient) after start of therapy, patients provided fecal 
samples for measurements of calprotectin and lactoferrin and blood samples for serum 
CRP. At week 12 (week 10 for the adalimumab-treated patient), each patient underwent a 
post-treatment ileocolonoscopy for evaluation of endoscopic response and scoring of the 
CDEIS. Clinical activity was scored according to the CDAI (Best et al 1976). 
1.2.2 Patients in Study IV 
Of the 15 patients in Study III, 13 participated in Study IV. The control group for this study 
comprised 14 non-IBD patients who were referred for ileocolonoscopy for the following 
indications: change in bowel habits (n=3), diverticular disease (2), colorectal cancer 
follow-up (2), history of polyps (1) or adenoma (2), history of rectal bleeding (2), 
abdominal pain (1), and exclusion of CD in one patient with a history of perianal 
abscesses. In all control subjects, routine histologic analysis of ileal biopsies was normal.  
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2 Methods 
2.1 Endoscopic scoring 
Experienced gastroenterologists (T.S., H.N., U.T., M.F.) performed the ileocolonoscopies 
and graded findings according to the CDEIS (Mary et al 1989): The extent of surface 
showing disease, presence of mucosal superficial or deep ulcerations, and presence of 
either ulcerated or non-ulcerated stenosis were evaluated in each segment of the colon 
(right, transverse, left colon, and rectum) and ileum. The SES-CD (Daperno et al 2004) 
was also scored during all endoscopies and is decribed in more detail in the original 
publication (II).  
No validated endoscopic limits to remission or to endoscopically mild, moderate, or severe 
activity exist. Thus, in Studies I and III, somewhat arbitrarily, CDEIS <3 suggested 
inactive, 3 to 9 mildly, ≥9 to 12 moderately active, and ≥12 severely active disease. In 
Studies III and IV, endoscopic treatment response was defined as a 2- or 3-class change in 
the CDEIS or achievement of remission (CDEIS <3). Partial response was defined as a 1-
class improvement in endoscopic score.  
2.2 Histology 
2.2.1 Histology scoring  
During all endoscopies, four biopsy specimens—targeted at the most severely diseased 
area—were taken from the ileum, right, transverse, and left colon, and the rectum. If no 
lesions were present in the segment, the biopsies were collected from random sites in each 
segment. Routine histology was performed on specimens stained with hematoxylin and 
eosin. In Studies II and III, a single experienced gastrointestinal pathologist (P.K.) scored 
the histologic findings according to the scoring system for histologic abnormalities in 
Crohn’s disease mucosal biopsy specimens (D'Haens et al 1997, 1998). This scoring 
system is described in detail in original publications II and III.  
2.2.2 Biopsy specimens in Study IV 
During baseline and post-treatment endoscopies, two mucosal biopsy specimens were 
taken from the most severely diseased lesions from both the ileum and the colon for Study 
IV. If no lesions were present in the segment, the biopsies were collected from random 
sites in the ileum and colon. All samples were immediately deposited in cooled tubes 
including 0.9% saline solution and were delivered without delay to the laboratory and 
frozen at -70oC. Antibodies to CD4, CD8, IL-17, and Foxp3 served for 
immunohistochemical staining of the mucosal T cells.  Positive cells comprising the lamina 
 
 
 
 
52
propria were counted under a light microscope, followed by a quanitative real-time 
polymerase chain reaction (PCR) for detection of expression of IL-17A, Foxp3, IL-23A 
p19, and IFN-γ. Immunoenzymatic labeling, microscopic evaluation, and quantitative real-
time PCR are described in more detail in the original publication IV.  
2.3 Fecal calprotectin and lactoferrin assays and blood tests 
Fecal calprotectin was measured by a quantitative enzyme immunoassay (PhiCal Test, 
Calpro AS, Oslo, Norway; NovaTec Immunodiagnostica, Dietzenbach, GmBH, Germany). 
Lactoferrin was measured by a quantitative enzyme immunoassay (IBD-SCAN, Inverness 
Medical, Princeton, NJ, USA; Techlab, Blacksburg, VA, USA).  The upper limit of normal 
for fecal calprotectin was <100 µg/g, (Kolho et al 2006, von Roon et al 2007) and for fecal 
lactoferrin <7.25 µg/g of stool (manufacturer’s baseline value, Kane et al 2003).  Blood 
count, serum albumin, ESR, and CRP were determined as routine laboratory values. 
2.4 Statistics 
 Each value is presented as a median. For data analyses we used the Statistical Package for 
the Social Sciences for Windows software 14.0 (SPSS, Chicago, IL, USA). Correlations 
were analyzed with two-tailed Spearman´s rank order correlation coefficient (r). For 
nonparametric tests, the Mann-Whitney and Kruskall-Wallis tests served in exploring 
associations between activity groups. The Wilcoxon signed-rank test was used for 
comparisons between paired samples. Significance was set at 0.05. 
2.5 Ethical considerations 
For participation in these studies, all patients gave their informed written consent, 
approved by the ethics committee of the Helsinki University Central Hospital. 
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 Results  
1 Cross-sectional studies 
1. 1  Endoscopic activity and fecal markers 
The ileum was intubated in 95 (90%) of endoscopies. Calprotectin samples numbered 106 
and lactoferrin samples 104.  In all samples, median fecal calprotectin was 178 µg/g (range 
11 to 18575) and fecal lactoferrin 7.7 µg/g (range 0.0-2970.6).  The CDEIS was 5.4 (0-26), 
the SES-CD was 7 (0-31, unpublished data for the SES-CD, Sipponen et al), and S-CRP 
(n= 105) was <5 mg/l (range <5-211). Correlations of the CDEIS with the SES-CD, fecal 
markers, and the CDAI are presented in Figure 1. The SES-CD correlated with calprotectin 
(r=0.699) and lactoferrin (r=0.751) significantly (p<0.001). Fecal calprotectin correlated 
significantly with fecal lactoferrin (r=0.864, p<0.001). Correlation of the CDEIS with CRP 
was significant (r=0.553, p<0.001). CRP correlated significantly with calprotectin 
(r=0.618, p<0.001) and lactoferrin (r=0.607, p<0.001) (Sipponen et al, unpublished data). 
 
 
 
 
 
 
Figure 1. Correlations of a) the CDEIS with the SES-CD, b) the CDEIS with fecal 
calprotectin and lactoferrin, c) the CDEIS with the CDAI, and d) the CDAI with fecal 
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calprotectin and lactoferrin. CDEIS, Crohn’s disease index of severity; SES-CD simple 
endoscopic score for Crohn’s disease; CDAI, Crohn’s disease activity index 
1.1.1 Fecal markers according to endoscopic disease activity 
Endoscopic activity was classified according to CDEIS score into inactive (CDEIS 0 to 3, 
n=36, 34%), mildly active (CDEIS ≥3 to 9, n=38, 36%), and moderately (CDEIS ≥9 to 12, 
n=16, 15%) or severely active disease (CDEIS ≥12, n=16, 15%) disease. Fecal calprotectin 
and lactoferrin levels were significantly lower in patients with inactive than with active 
disease (CDEIS ≥3) (p<0.001). 
 
Endoscopically inactive disease 
In inactive disease, median calprotectin concentration was 63 µg/g (range 11-869), 
lactoferrin 1.9 µg/g (0.0-81.3), CDAI 60 (2-155), SES-CD 3 (0-7). Both fecal markers 
were significantly lower in this group than in mildly, moderately, or severely active disease 
(all p<0.001) Both fecal markers were normal in 24 of 36 (67%), calprotectin was normal 
in 25 (69%) and lactoferrin in 31 (86%) patients; 16 (44%) of calprotectin values were 
even below the manufacturer’s reference limit for normal (50 µg/g). Despite 
endoscopically inactive disease, both fecal markers were elevated in five (14%) patients: 
upper-GI disease occurred in three patients, one had erosive pseudopolyps in the colon, and 
one had a superficial ileocolonic anastomosis ulcer. 
Endoscopy revealed no ulcers in 22 patients (66%) in the endoscopically inactive 
group. Of these, the majority, 18 (82%) had either a normal calprotectin or lactoferrin 
concentration, and both fecal markers were normal in 14 (64%) patients.  
 
Endoscopically mild disease 
Of 106 endoscopies, 38 (36%) indicated endoscopically mildly active disease. Median 
calprotectin concentration was 170 µg/g (range 17 to 2440), lactoferrin 6.8 µg/g (0.0 to 
891.3), CDAI 69 (-8 to 236), and SES-CD 8 (1 to 13).  In mildy active disease, fecal 
calprotectin and lactoferrin values differed significantly from those in endoscopically 
moderate or severe disease (all p<0.001). In 25 samples (66%), calprotectin concentration 
was abnormal. Lactoferrin was available for 37 patients and was elevated in 17 (46%) 
samples. Despite mild endoscopic activity, both fecal markers were normal in 11 (29%)  
patients (8 of these had either an ulcerated or a fibrotic stricture in the ileocolonic 
anastomosis). On the other hand, although endoscopic activity was considered mild, five 
patients (13%) had a considerably elevated calprotectin (>1000 µg/g) and two (5%) a high 
lactoferrin (>100 µg/g) concentration.  
 
Endoscopicaly moderate or severe disease 
In patients with endoscopically moderately or severely active disease (n=32), all fecal 
calprotectin and lactoferrin values were abnormal. Median calprotectin value was 1158 
µg/g (123 to 18575), lactoferrin 105 µg/g (10.6 to 2970.6), CDAI 133 (-7 to 605), and 
SES-CD 15 (7 to 31).  Of the 32, 22 (69%) had a calprotectin concentration over 1000 µg/g  
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and 16 (50%) a lactoferrin concentration over 100 µg/g. Based on the CDAI, 16 (56%) had 
clinically inactive disease, although their endoscopic activity was considered moderate or 
severe. Median SES-CD in this group was 15 (range 7 to 31). Compared to levels in 
inactive or mildly active disease, fecal calprotectin and lactoferrin were significantly 
higher in moderately or severely active disease (p<0.001). 
1.1.2 Fecal markers according to disease location  
 
Of the whole study group, those with strictly ileal disease (n=22) showed a significant 
correlation of their CDEIS with lactoferrin (r=0.678, p<0.001), but not with calprotectin 
(r=0.316, p=0.151). Interestingly, when purely ileal and ileal + upper GI tract disease were 
combined (n=28), calprotectin also correlated weakly with the CDEIS (r=0.434, p=0.021), 
but not with the SES-CD (r=0.317, p=0.101) (for SES-CD unpublished data, Sipponen T et 
al). Correlations of lactoferrin with the CDEIS (r=0.525, p=0.005) and SES-CD were 
significant (r=0.485, p=0.01).  In the subgroup of patients with an intubated ileum and 
histologic analysis available (n=21), however, fecal markers in ileal ± upper GI tract 
disease failed to correlate with ileal SES-CD (for calprotectin r=0.317 and for lactoferrin 
r=0.180, p>0.05).  
In colonic or ileocolonic CD ± upper GI tract disease (n=78), both calprotectin and 
lactoferrin correlated significantly with endoscopic scores (calprotectin with the CDEIS 
r=0.770, with the SES-CD r=0.758, lactoferrin with the CDEIS r=0.805, with the SES-CD 
r=0.781, all p<0.001). Table 8 presents median fecal-marker concentrations by disease 
location and activity. 
In all location groups with upper GI-tract data pooled, fecal calprotectin was 
significantly higher in active than in inactive disease. Lactoferrin was significantly higher 
in active ileocolonic or colonic disease than in inactive, but not in ileal disease. Fecal 
markers were significantly higher in active colonic (both p<0.001) or ileocolonic 
(calprotectin p=0.028, lactoferrin p=0.004) than in ileal disease. In inactive disease, 
concentration differences in fecal markers between disease locations were non-significant.  
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 Table 8. Fecal markers by disease location and activity. 
   
  
 
 Active disease: CDEIS ≥3. Median values.  
* active group, 4 patients, inactive group, 2 patients had known upper GI-tract  disease. ** 
active group, 3 patients, inactive group, 3 patients had  known upper GI-tract disease. 
 
1.1.3 Sensitivity, specificity, PPV, and NPV of fecal markers in predicting 
endoscopically active disease 
 
Among the sensitivity, specificity, PPV, and NPV values of fecal markers, the CDAI, and 
CRP, values with a cutoff 80 for the CDAI and 10 mg/l for CRP are previously 
unpublished (Table 9). In predicting endoscopically moderately or severely active disease 
(CDEIS ≥ 9), sensitivity, specificity, PPV, and NPV for fecal calprotectin ≥1000 µg/g and 
for lactoferrin ≥50 µg/g were 69%, 93%, 82%, and 87%, and 65%, 96%, 87%, and 83%, 
respectively.  
 
 
 
 
 
 
 
 
 
 
 
Disease (number) 
 
Fecal calprotectin  
μg/g (range) 
 
Fecal lactoferrin 
μg/g (range) 
Ileal disease* 
    active disease (19) 
    inactive disease (9) 
 
180 (35-1294) 
 62 (37-156), p=0.025 
 
7.7 (0.0-68.5) (n=18) 
2.1 (0.0-54.1), p=0.117 
Colonic disease 
   active disease (14) 
   inactive disease (8) 
 
1383 (45-6543) 
41 (21-136), p<0.001 
 
179.4 (2.9-802.1) n=13 
0.04 (0.0-1.9), p<0.001 
Ileocolonic  disease** 
   active disease (37) 
   inactive disease (19) 
 
 
609 (17-18575) 
63 (11-869), p<0.001 
 
29.9 (0.0-2970.6) 
2.1 (0.0-81.3), p<0.001 
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Table 9. Sensitivity, specificity, positive predictive value PPV, and negative predictive  
value NPV of variables in detecting endoscopically active disease (CDEIS ≥ 3). 
 
 
 
1.2 Clinical activity and fecal markers 
The median CDAI in the study group was 74 (range -8 to 613). Correlations of the CDAI 
with the CDEIS and fecal markers are presented in Figure 1. The CDAI correlated 
significantly also with the SES-CD (r=0.373, p<0.001), but correlations of fecal markers 
with endoscopic scores were stronger. In Table 10, endoscopic scores and fecal markers 
are grouped according to clinical activity. According to the CDAI, 85 patients had inactive 
disease (CDAI <150), and 21 had active disease (CDAI ≥150).  Although the CD was 
clinically inactive, fecal calprotectin was elevated (>100 µg/g) in 48 of 85 (56%) and 
lactoferrin in 33 of 83 (40%) patients. In clinically inactive disease, fecal calprotectin was 
considerably elevated (>1000 µg/g) in 14 (16%) patients and lactoferrin (>100 µg/g) in 8 
(10%). The majority of the 21 patients with clinically active disease, however, had 
abnormal calprotectin (n=20; 95%) and lactoferrin (n=19; 90%) concentrations.   
 
 
Table 10. Endoscopic scores and fecal markers by clinical disease activity.  
 
 
Values presented as median (range). * p<0.001 between clinical activity groups. 
  
Sensitivity 
     %          
 
Specificity 
% 
   
PPV 
% 
    
NPV 
% 
F-calprotectin ≥100 μg/g 81 69 84 66 
F-calprotectin ≥200 μg/g 70 92 94 61 
F-lactoferrin ≥7.25 μg/g 71 83 89 60 
F-lactoferrin ≥10 μg/g 66 92 94 59 
CDAI  ≥80 56 65 78 46 
CDAI  ≥150 27 94 91 40 
S-CRP  ≥5 mg/l 48 91 91 48 
S-CRP  ≥10 mg/l 29 95 91 44 
 
 
CDAI 
 
CDEIS 
 
SES-CD 
 
Fecal calprotectin 
μg/g 
 
Fecal lactoferrin 
μg/g 
<150 4.4 (0.0-26.0) 6 (0-21) 127 (11-6453) 4.2 (0.0-891.3) 
 
≥150 
 
10.2 (0.2-25.3)* 
 
13 (4-31)* 
 
1173 (53-18575)* 
 
92.4 (5.3-2970.6)* 
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1.4 Histologic findings and fecal markers 
The histologic score was available for 87 endoscopies. Calprotectin results numbered 87 
and lactoferrin 85.  In the whole study group, median total histology score was 12 (range 0-
45), colon score 7 (0-38), and ileum score 4 (0-11). For ileal disease alone, ileal histology 
score was 6 (0-11). In ileocolonic or colonic disease, colon histology score was 13 (0-38) 
and ileal score was 4 (0-11). Of 87 endoscopies, 15 SES-CD values were ≤3 and only two 
of these had signs of increased polymorphonuclear cells in the epithelium or lamina propria 
(Sipponen et al, unpublished data). 
Although ileal histology score correlated significantly with ileal endoscopic score, it 
failed to correlate with fecal markers. In ileocolonic or colonic disease, correlations of 
fecal markers with histology score were significant (Table 11). 
 
Table 11. Correlations of fecal markers with the SES-CD and histologic scores. 
 
 
* p<0.05; ** p<0.001. 
1.4.1 Histology in patients with normal fecal-marker concentration 
Patients with normal fecal calprotectin or lactoferrin had significantly lower endoscopic and 
histologic scores than did those with elevated fecal markers:  total SES-CD (p<0.001), 
colon SES-CD (p=0.004 for calprotectin, p<0.001 for lactoferrin), total histology score 
(p<0.001), and colon histology score (p=0.002). 
 
 
        Fecal calprotectin 
ileal disease      ileocolonic/colonic    
          Fecal lactoferrin 
     ileal       ileocolonic/colonic    
Total SES-CD 
  ileal SES-CD 
  colonic SES-CD 
0.050                  0.733** 
0.317                  0.171                  
-                          0.642**              
0.280                0.748** 
0.180                0.226 
-                        0.627** 
SES-CD variables : 
  presence of ulcers 
  extent of ulcerated           
  surface 
  extent of affected  
  surface 
  presence of narrowings 
 
0.016                  0.670**                 
0.010                  0.688**          
 
0.251                  0.645**          
 
-0.094                 0.141     
 
0.483*               0.666** 
0.289                 0.697** 
 
0.113                 0.684** 
 
      0.045                 0.178 
Total histology score 
  ileal histology  
  colon histology 
0.147                  0.617**  
0.311                  0.178 
-                          0.563**              
-0.008                0.611** 
0.291                 0.255* 
-                         0.543** 
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Ileal disease  
Of 21 patients with ileal CD, 10 had normal fecal calprotectin, and 13 had normal 
lactoferrin. Compared to patients with elevated fecal markers, no significant differences 
occurred in ileal SES-CD or ileal histology scores (all p>0.05). The four patients with 
normal lactoferrin and elevated calprotectin showed an increased number of both 
polymorphonuclear neutrophils and mononuclear cells in the lamina propria and of 
polymorphonuclear cells in the epithelium. Of the patients with normal calprotectin, half 
had no or only architectural changes in the ileal biopsy specimens.  
 
Colonic or ileocolonic disease 
Of 66 patients with ileocolonic or colonic disease, calprotectin was normal in 21 and 
lactoferrin in 26. With normal calprotectin, median colon SES-CD was 3 (range 0-7), and 
colon histology score was 5 (0-25), both significantly (p<0.001) lower than in the 45 patients 
with an elevated calprotectin (colon SES-CD 9, range 0-26; colon histology score 18, range 
0-38). Accordingly, in patients with normal lactoferrin, colon SES-CD was 3 (0-9) and 
histology score 5 (0-25), and both of these were significantly (p<0.001) lower than in those 
with elevated lactoferrin values (n=39, colon SES-CD 10, range 0-26, and colon histology 
score 18, range 0-38).  
Nine biopsy specimens showed either no changes or architectural changes only. Of these, 
calprotectin was mildly elevated (140 µg/g) in one, whereas lactoferrin was normal in all 
nine. Furthermore, of 21 patients with normal calprotectin, 11 (52%) showed no histologic 
changes or showed architectural changes only.   
  
2 Treatment studies 
2.1 Fecal markers and endoscopic findings during anti-TNFα therapy 
Of 30 endoscopies, the ileum was reachable in 28. Before the introduction of anti-TNFα 
therapy, the CDEIS indicated mildly or moderately active (CDEIS 3-12) disease in five 
patients (33%) and severe (CDEIS ≥12) in nine (60%). One patient with active disease in 
the neoterminal ileum had a low baseline CDEIS (1.8). As a result of therapy, both fecal 
markers, S-CRP, endoscopic, and clinical scores declined significantly from their baseline 
levels (Table 12). 
Of 15 patients, 11 (73%) were endoscopically defined as  treatment responders, one 
was a partial responder, and 3 were nonresponders. Of responders, five achieved remission 
(CDEIS <3). Their fecal calprotectin declined from 1891 μg/g (range 813-2434) to 27 μg/g 
(13-130) and lactoferrin from 92.4 μg/g (35.5-235.6) to 1.9 μg/g (0.0-2.1).  
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Changes in CDEIS (ΔCDEIS) correlated with ΔCDAI (r=0.679, p=0.005), 
Δcalprotectin (r=0.561, p=0.030), and Δlactoferrin (r=0.600, p=0.023), but failed to 
correlate with Δileal histology score (r=0.058, p=0.845), or Δcolon histology score 
(r=0.369, p=0.090). Correlations of Δcalprotectin and Δlactoferrin concentrations with 
Δileal histology score or Δcolon histology score were also nonsignificant (p>0.05). 
 
2.2 Changes in mucosal T cell markers during anti-TNFα therapy 
Compared to controls both before and after therapy, the number of IL-17+ cells in ileal 
(before therapy p<0.0005 and after p=0.0005) or colonic specimens (p=0.015 and p=0.042, 
respectively) was increased. Moreover, the number of Foxp3+ cells was increased 
compared to control numbers in ileal specimens before (p=0.023) and after (p=0.005) 
therapy. In colonic specimens, the number of Foxp3+ cells was increased compared to 
controls only after therapy (p=0.032). During anti-TNFα therapy, changes in the number of 
IL-17+ or Foxp3+ cells in ileal or colonic specimens were nonsignificant (all p>0.05). In 
ileal or colonic specimens, the number of CD4+ or CD8+ cells showed no significant 
difference before or after the therapy between the groups (all p>0.05). Table 13 shows the 
changes in mucosal IL-17, IL-23, Foxp3, and IFN-γ specific messenger ribonucleic acid 
(mRNA) expression in ileal and colonic biopsy specimens compared to controls.  
In ileal specimens,  the relation of  IL-17+ cells to CD4+ cells (calculated for each 
individual)  was higher than among control subjects  both at 0 and 3 months (p=0.006 and 
p=0.0013). A significant decrease occurred in the relation of IL-17+ cells to CD4+ cells 
after introduction of anti-TNFα treatment (p=0.047). The relation of IL-17+ cells to Foxp3+ 
cells was higher in the patients’ baseline samples than in the post-treatment specimens 
(p=0.038). 
At baseline, the ileal biopsy specimens showed no significant correlations between 
FoxP3+ or CD4+ cells and the CDEIS or between number of IL-17+ cells or IL-17 mRNA 
expression and the CDEIS. After anti-TNFα induction, however, the number of IL-17+ 
cells and the CDEIS (r=0.806, p=0.007) and IL-17 mRNA expression and the CDEIS 
(r=0.736, p=0.038) showed a close correlation. The number of CD8+ cells showed a 
positive correlation with the CDEIS after the therapy, but not in the baseline samples. No 
significant correlation of calprotectin with IL-17+ cells was detectable (r=0.683, p>0.05). 
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Table 12. Fecal markers, endoscopic, histologic, and clinical scores and S-CRP during 
anti-TNFα therapy. Values before therapy compared to values at 12 weeks. 
 
 
Median values (range). CDEIS, Crohn’s disease index of severity; CDAI, Crohn’s disease 
activity index. 
 
 
 
 
 
 
 
 
               
 
Before 
therapy 
 
2 weeks  
 
8 weeks  
 
12 weeks 
CDEIS 
 
 
 
Colon 
histology 
 
Ileum 
histology 
13.0  
(1.8-25.3) 
 
 
23 (0-38) 
 
 
7 (0-11) 
- 
 
 
 
- 
 
 
- 
- 
 
 
 
- 
 
 
- 
4.8 
 (0.0-11.2) 
 p=0.002 
 
11 (0-25) 
p=0.002 
 
4 (0-9) 
p=0.022 
 
CDAI 
 
158  
(49-605) 
 
77  
(13-197) 
 
68  
(26-192) 
 
66 (24-202) 
p=0.005 
 
F-calprotectin 
μg/g 
 
1173  
(88-15326) 
 
216  
(24-2349) 
 
325  
(15-20899) 
n= 14 
 
130  
(13-1419) 
p=0.001 
 
F-lactoferrin 
μg/g 
 
 
S-CRP 
mg/l 
 
105.0  
(4.2-1258.9) 
 
 
10 (< 5-54) 
n=14 
 
6.7  
(0.9-356.8) 
 
 
< 5 (< 5-11) 
 
7.1  
(0.0-5400.6) 
n= 12 
 
< 5 (< 5-19) 
 
2.7  
(0.0-228.5) 
n= 14 
p=0.001 
< 5 (< 5-6) 
p=0.005 
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Table 13.  IL-17-, IL-23-, Foxp3-, and IFN-γ-specific mRNA expression in ileal and 
colonic biopsy samples taken before and 3 months after start of anti-TNFα-therapy. Values 
compared to controls. Median (range) mRNA levels expressed as relative units for each 
group.   
 
 
 *p<0.05, **p<0.01, ***p<0.001.   
 
  
before therapy 
 
 at 3 months 
 
Controls 
Ileum 
IL-17 
 
128.0 (30-325) 
 
67.5 (30-615) 
 
    30.0 (30-419) 
      IL-23 373.0 (322-804)* 444.5 (235-542)*     225.0 (153-706) 
Foxp3 611.0 (15-792)* 104.5 (15-891)*     20.5 (15-220) 
IFN-γ 19.6 (8.6-230)*** 14.0 (1.0-37.6)*     1.0 (1.0-6.0) 
Colon 
IL-17 
 
133.5 (30-588)* 
 
79.0 (30-1607) 
 
    30.0 (30-144) 
IL-23 167.0 (72-405) 240.0 (74-983)     252.0 (9-392) 
Foxp3 311.5 (63-694)** 135.5 (15-1284)     49.0 (15-252) 
IFN-γ 45.0 (2.0-249.7)** 15.7 (1.0-122.2)*     1.0 (1.0-5.6) 
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Discussion 
1 Fecal markers as surrogate markers of endoscopic activity 
Our study showed that fecal calprotectin and lactoferrin correlated closely with the 
validated endoscopic scores CDEIS and SES-CD. These correlations were stronger than 
were correlations of endoscopic scores with clinical acitivity assessed with the CDAI or 
with CRP. Furthermore, in endoscopically inactive disease (CDEIS <3) both fecal markers 
were significantly lower than in endoscopically mild, moderate, or severe disease.  
Several studies have shown fecal calprotectin to be higher in clinically active CD than 
in inactive disease (Tibble et al 2000a, 2002, Costa et al 2003, Carroccio et al 2003, 
Dolwani et al 2004, Wassell et al 2004, Gaya et al 2005, Scarpa et al 2007, Schröder et al 
2007). Similarly, fecal lactoferrin has been elevated in clinically active disease (Uchida et 
al 1994, Kayazawa et al 2002, Kane et al 2003, Dai et al 2007, Schröder et al 2007, 
Walker et al 2007). In these studies and in studies detecting fecal calprotectin 
concentrations in clinical CD remission (Roseth et al 1999, Tibble et al 2000b, Costa et al 
2005), fecal-marker concentrations have been elevated even in clinically inactive disease. 
This is in keeping with earlier studies that have detected, based on fecal excretion of 111In-
labeled granulocytes, low-grade inflammation in symptomless CD patients (Saverymuttu 
1986) and poor correlation of their clinical activity score CDAI with endoscopic findings 
(Modigliani et al 1990, Cellier et al 1994). In our study, almost all patients with clinically 
active disease had abnormal fecal markers, confirming that their symptoms were most 
probably a result of intestinal inflammation and not a sign of noninflammatory conditions 
(such as functional symptoms, stenosis, or bile acid malabsorption). Fecal markers were, 
however, abnormal in a considerable number of patients with clinically inactive disease 
and were in some of these patients even highly elevated. The CDAI seems thus to 
underestimate mucosal inflammation, and a remission based only on the CDAI cannot be 
intepreted as complete. An adjusted cutoff of the CDAI (>80) has been shown to improve 
diagnostic accuracy (Langhorst et al 2008). In the present study, a similar adjusted cutoff 
doubled the sensitivity of CDAI in detecting endoscopically active disease, but this 
remained still lower than the sensitivities of fecal markers.  
Crohn’s disease is not associated with perforating complications or fibrostenosis early 
in its onset. The majority of CD patients start with inflammatory lesions. Continuing 
inflammation in symptomless patients may indicate a stage of active ongoing inflammation 
which can progress to clinical relapse or complications. On the other hand, achievement of 
mucosal healing appears to correlate with fewer hospitalizations (Rutgeerts et al 2006). 
Therefore, detection of intestinal inflammation even in nonsymptomatic patients is 
valuable. Finding reliable surrogate markers for endoscopic activity, especially in CD, is 
thus important. One of the first studies showing the importance of fecal calprotectin as a 
surrogate marker of endoscopic activity was Roseth and coworkers’ report (1997) showing 
in UC patients a close correlation of fecal calprotectin with endoscopic and histologic 
activity. Studies showing calprotectin to be significantly elevated in IBD or CD patients 
compared to those with nonorganic disease have performed endoscopies, but CD findings 
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were not scored with a validated endoscopic index (Limburg et al 2000, Tibble et al 2000a, 
2002, Schröder et al 2007). In a study comparing calprotectin and S100A12 in detecting 
inflammation, endoscopic findings of CD patients were scored according to the SES-CD, 
but the histology score served as the reference standard for absence or presence of 
inflammation, and correlations of fecal markers with the SES-CD results were not 
published (Kaiser et al 2007). A recent study of 164 CD patients scored endoscopic 
findings according to the SES-CD and showed a significant correlation of both fecal 
markes with endoscopic disease activity (Jones et al 2008). The SES-CD served as an 
endoscopic score also in two studies of Schoepfer and coworkers (2007, 2008).  In 
moderately or severely endoscopically active CD (SES-CD ≥20), calprotectin as well as 
lactoferrin was significantly higher than in mild or inactive disease (Schoepfer et al 2008). 
Two studies grading endoscopic findings of both UC and CD on a scale from 0 to 3 (from 
“no inflammation” to mild, moderate, or severe inflammation) showed a close correlation 
of endoscopic activity with fecal calprotectin (Langhorst et al 2008, D’Inca et al 2007). In 
Langhorst and coworkers’ research (2008), lactoferrin also correlated closely with 
endoscopic inflammation in CD. In D’Inca and coworkers’ research (2007), lactoferrin—
analyzed with a qualitative ELISA—correlated with histologic score, but not with 
endoscopic activity.   
In the present study detecting endoscopic findings of a higher number of CD patients, 
both fecal markers showed a close correlation with endoscopic disease activity as defined 
by the CDEIS or SES-CD. A different finding was published by Denis and coworkers 
(2007): With a CDEIS cutoff of ≤6 for endoscopically mild disease, their 28 patients with 
clinically active CD and a normal CRP failed to show any correlation of their CDEIS 
scores with fecal calprotectin. In that study over half the patients had pure ileal disease in 
which the CDEIS upper limit of 6 is probably too high for minor activity. In our study, 
with a larger population showing a positive correlation of fecal markers with endoscopic 
grading, the cutoff for endoscopically inactive disease was set lower (CDEIS <3), and mild 
activity was scored between 3 and 9.  
Although the CDEIS has served in several treatment studies, endoscopic remission in 
CD is not clearly defined, and no specific numeric cutoff CDEIS or SES-CD value for 
remission has been determined (Sandborn et al 2002, Hommes et al 2004, Rutgeerts et al 
2007). In patients achieving clinical remission after corticosteroid treatment, the CDEIS 
was 6.9±5.5 (mean ± standard error of mean), and in those achieving both endoscopic (no 
lesions or only scars, or minor lesions with at least “a 2-grade decrease on the 5-grade 
scale”) and clinical remission it was 2.1±1.7 (Modigliani et al 1990). In another work, 
patients in endoscopic remission (no lesions or scarred lesions only or “minor lesions with 
at least a two-grade decrease on the six-grade scale of endoscopic severity and no residual 
deep ulcers”) after 3 to 7 weeks’ steroid therapy had a CDEIS of 2.0±0.3, and patients in 
clinical but not endoscopic remission achieved a CDEIS 5.1±0.7 after prolonged steroid 
therapy (Landi et al 1992). A study by Mary and coworkers (2005)—published as an 
abstract—revisited the data collected for validation of the CDEIS; it suggested  a CDEIS 
cutoff value for endoscopic remission of between six and seven (D´Haens 2007). CDEIS 
values close that level were achieved in patients treated with a single 5 mg/kg infliximab 
infusion: the CDEIS declined from baseline level 15.1±6.9 to 6.4±5.1 at week four 
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(D’Haens et al 1999). Accordingly, patients treated with a three-dose induction with 
infliximab showed a significant reduction in the CDEIS at week 10, and with maintenance 
therapy (every eighth week) at week 54 (median CDEIS was under 3) (Geboes et al 2005). 
In that trial, a CDEIS less than 5 was considered mild disease, 5 to 15 moderate, and >15 
severe disease.  
Some infliximab-response studies define complete mucosal healing as “complete 
absence of mucosal ulcers observed at baseline” (Rutgeerts et al 2004, 2006). When 
endoscopic remission is defined thus, even having one single aphthous ulcer in otherwise 
healed mucosa is not considered remission. Ideally, only a CDEIS as low as zero should be 
considered complete endoscopic remission. In the present study, for practical reasons, we 
decided to give a numeric cutoff for remission (CDEIS <3). This allows minor changes in 
CD mucosa in endoscopic remission.  It is comparable to CDEIS values in endoscopic 
remission from Modigliani and Landi et al’s studies described above (Modigliani et al 
1990, Landi et al 1992), but considerably lower than the cutoff suggested by Mary and 
coworkers (2005). Accordingly, a SES-CD <3 was defined as endoscopically inactive 
disease.  With these cutoff values for CDEIS and SES-CD, we showed fecal neurophil-
derived proteins to be significantly lower in endoscopic remission than in active disease. A 
CDEIS <3 for remission served also in our anti-TNFα study.  
A normal fecal-marker value is possible to achieve even in CD. In the present study, 
the majority of CD patients with inactive disease had a normal fecal calprotectin or 
lactoferrin concentration. In detecting endoscopically active disease, the sensitivity of a 
normal fecal-marker level (50 or 100 μg/g) is good, but the specificity is lower.  Clinical 
practice may require an adjusted upper limit for normal fecal-marker concentration in CD. 
We found reasonable sensitivity and a good specificity and PPV for active disease with a 
cutoff value for calprotectin at 200 μg/g and for lactoferrin at 10 μg/g, but the negative 
predictive value of these cutoffs was less satisfactory. In detecting moderate or severe 
endoscopic activity, cutoff values for calprotectin of 1000 μg/g and lactoferrin of 50 μg/g 
had fairly good NPV. In clinical practice, a low fecal-marker value excludes active 
inflammation, and with a considerably elevated value, active inflammation is very likely. 
These markers are, however, not ideal, and in future other proteins such as S100A12 may 
even replace calprotectin and lactoferrin, but more studies are needed for confirmation 
(Kaiser et al 2007). 
Compared to endoscopy, one benefit of neutrophil-derived proteins is the ability to 
detect inflammation throughout the GI tract. When ileocolonoscopy fails to show any 
inflammation, and a fecal-marker concentration is elevated, the upper GI tract and small 
bowel reguire examination. We did not examine the upper GI tract systematically during 
our study, but any known upper-GI tract disease was classified according to the Montreal 
classification (Silverberg et al 2005). For ileal ± upper-GI disease our results are somewhat 
controversial; it seems, however, that in ileal CD with limited disease extension, fecal 
calprotectin and lactoferrin are not as clearly elevated as in colonic or ileocolonic disease. 
A study from Mayo Clinic supports our findings: Correlations between fecal markers and 
isolated ileal disease were at best weakly positive, but were strong in colonic disease 
(Jones et al 2008). A similar but nonsignificant trend at least with lactoferrin and PMN-E 
 
 
 
 
66
emerged in Schröder and coworkers’ study (2007). Calprotectin also correlates with 
disease extent and severity (Bunn et al 2001b, Fagerberg et al 2007).  
 A different result emerged in research on postoperative CD, where fecal-marker 
concentrations in ileal involvement were similar to concentrations in anastomotic or 
colonic involvement (Scarpa et al 2007). Moreover, a study including 49 CD patients (27 
with ileal CD, 6 with colonic, and 16 with ileocolonic disease) failed to reveal any 
influence of disease site on calprotectin values (Costa et al 2003), and another study, one 
of pediatric patients, showed a non-significant fecal calprotectin difference between ileal 
CD and colonic or ileocolonic disease (Bremner et al 2005). Furthermore, serum or 
mucosal (achieved from the cecum only) calprotectin levels between disease-location 
groups were similar (Leach et al 2007). A recent study, however, showed that release of 
calprotectin and S100A12 protein was strongly dependent on disease location in 
endoscopically and histologically active CD: In ileal disease, release was minor from sites 
of inflammation compared to release in colonic inflammation (Foell et al 2008). This may 
explain our differing results by disease location. The small number of ileal CD patients, 
with the majority of them having a stricturing phenotype—although endoscopic and 
histologic inflammation was detectable—may bias the results.  A larger study is needed of 
fecal markers in small bowel CD or strictly ileal CD.  
     In the present study, fecal calprotectin and lactoferrin gave fairly similar results in 
detecting endoscopically active disease. A study finding lactoferrin correlating better with 
CRP than does calprotectin suggests that lactoferrin reflects more systemic inflammation 
but calprotectin reflects a local phenomenon (Scarpa et al 2007). This was speculated to be 
a consequence of differences in the release mechanisms of these two proteins. Although 
lactoferrin is a neutrophil-degranulation protein, and calprotectin is among the DAMPs, the 
present study does not support Scarpa et al’s finding (2007), as both fecal markers 
correlated significantly with CRP. Combination of calprotectin with other neutrophil-
derived markers (lactoferrin or PMN-E) seems not to improve the diagnostic accuracy of 
calprotectin (Schröder et al 2007).  
Our study included only patients with known CD. It does not answer the question 
whether fecal markers should be included in the diagnostic workup of patients complaining 
of abdominal symptoms (diarrhea, lower abdominal pain). Data from several studies, 
however, support this strategy (Tibble et al 2000a, Carroccio et al 2003, Costa et al 2003, 
D'Inca et al 2007, Schoepfer et al 2007, 2008). In a clinical setting, it seems that detection 
of fecal calprotectin or lactoferrin would be of more benefit than measurement of ESR or 
CRP—tests often included in the diagnostic workup of patients with abdominal symptoms.  
It is suggested that the diagnosis of IBD can be excluded in patients who have a negative 
calprotectin test and who fulfill the Rome criteria of IBS (Aadland et al 2002). Those with 
an elevated concentration, once infection is ruled out, could be referred to endoscopy. This 
strategy could reduce the number of endoscopy referrals, and on the other hand, possibly 
shorten the interval between IBD symptoms and diagnosis. What should be noticed, 
however, is that patients with alarming symptoms or findings like anemia, weight loss, or 
rectal bleeding are likely to need endoscopic investigation regardless of fecal-marker 
values.   
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It should be remembered that fecal markers cannot replace IBD patients’ surveillance 
endoscopies performed for detection of colonic dysplasia. Possibly fecal markers could, 
however, aid in better timing of these endoscopies: the ideal time for surveillance 
colonoscopy would be when fecal marker concentration is low, making possible dysplastic 
findings easier to detect.  
2 Fecal markers and histologic activity 
The present study showed that fecal calprotectin and lactoferrin concentrations correlated 
significantly with histologic activity in ileocolonic and colonic disease. The majority of 
patients with endoscopically inactive disease had no signs of increased infiltration of 
neutrophils in the epithelium or lamina propria. Furthermore, fecal markers were higher in 
the more severe histologic findings than in those with lower histologic activity. No such 
difference was evident in ileal disease.  
In pediatric and adult IBD, fecal calprotectin correlates with histologic grades of 
inflammation (Roseth et al 1997, Limburg et al 2000, Bunn et al 2001b), and in histologic 
remission, fecal calprotectin has been significantly lower than in histologically active CD 
(Fagerberg et al 2007, Canani et al 2008). Furthermore, low calprotectin levels have been 
detectable in patients with histologic remission (Roseth et al 1997, Fagerberg et al 2007). 
In keeping with this, in the present study, half the patients with a normal calprotectin value 
had no signs of inflammation in their biopsy specimens. In a pediatric IBD study, a 
calprotectin cutoff value of 85.7 μg/g gave a sensitivity of 93% and a specificity of 82% in 
detecting microsopically active colonic inflammation (Fagerberg et al 2007). In another 
study, a higher calprotectin cutoff value of 143 μg/g has been suggested for discrimination 
in IBD between histologically active disease and remission (Canani et al 2008).  When 
histologic relapse was studied retrospectively in 73 quiescent IBD patients, for the 32 
presenting with histologic relapse, a calprotectin value of 275 μg/g was a sensitive and 
specific marker (Diamanti et al 2008). In that study, of 18 nonrelapsed CD patients, 5 
presented with a fecal calprotectin concentration over 275 μg/g and 4 of these had small 
bowel disease. Changes according to disease location were, however, statistifically 
nonsignificant (Diamanti et al 2008). 
Histologic remission is not clearly defined (Sandborn et al 2002). Biopsy specimens 
represent only a tiny area of the lesion from which they come, and a sampling error may 
bias the results in either direction—toward greater or lesser severity. Sampling error may 
be the reason for the present anti-TNFα study’s failing to show a significant correlation of 
changes in histologic score with changes in endoscopic score or with fecal calprotectin 
and lactoferrin concentrations. Fecal markers seem to represent the global intestinal 
inflammation better than do the biopsy specimens. Obtaining biopsy specimens only for 
estimation of CD activity thus may be unnecessary. 
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3 Fecal markers in monitoring therapy 
Calprotectin has been shown to predict mucosal healing in IBD (Roseth et al 2004). In that 
study, IBD patients in clinical remission with a normal calprotectin concentration (<50 
mg/l) were included. In all except one patient, the endoscopic appearance of the mucosa 
was normal, and in the majority histologic findings also showed complete mucosal healing. 
Median calprotectin value in CD patients was 35 mg/l. A small number of CD patients (n= 
6) had calprotectin data from a previous active phase, and these values were significantly 
higher than in remission.  A decline in fecal calprotectin during infliximab therapy has 
been reported in two patients (Aadland and Fagerhol 2002) and in fecal lactoferrin in five 
pediatric patients (Buderus et al 2004). Our prospective study supports these results: It 
showed a significant decline in both fecal markers during anti-TNFα therapy and 
normalization of markers in patients achieving endoscopic remission.   
     Objective monitoring of treatment success is important, especially when treatment 
requires expensive biological drugs. Based on our findings, fecal calprotectin and 
lactoferrin are reliable surrogate markers of mucosal healing. During anti-TNFα therapy, 
endoscopic monitoring of CD activity can be replaced with measurements of either of the 
fecal neutrophil-derived markers.  The one exception may be a patient with ileal disease 
and normal baseline fecal-marker concentration.  
     During clinical trials, normalization of the CDAI still widely serves as a primary 
endpoint of succesful therapy. Rather than the CDAI, fecal neutrophil-derived proteins, 
however, might serve as objective markers of disease activity. In Study III, calprotectin 
more than 200 μg/g and lactoferrin >10 μg/g served as surrogate markers of active disease. 
Criteria of fecal-marker concentrations for successful treatment remain unsettled, requiring 
studies larger than the present one.  
     Studies showing calprotectin to predict relapse in clinically inactive IBD have used 
various cutoff concentrations (250, 150, 130 μg/g) (Tibble et al 2000b, Costa et al 2005, 
D’Inca et al 2008). Although in Tibble and coworker’s trial (2000b) a 50 mg/l cutoff (new 
assay: 250 μg/g) predicted relapse in both UC and CD, the trial by Costa and coworkers 
(2005)  failed to predict relapse in CD (cutoff for calprotectin >150 μg/g), probably due to 
their low number of patients with colonic CD. In the latest study, a 130 μg/g cutoff seemed 
to predict relapse in UC or in colonic CD (D’Inca et al 2008). No corresponding data on 
lactoferrin are available.  
   IL-17 seems to augment TNFα-induced inflammatory responses, and interactions of 
TNFα and IL-17 potently mobilize neutrophils (Andoh et al 2008). In Study IV, we 
failed—probably due to a low number of patients—to detect during anti-TNFα therapy a 
significant correlation with IL-17-positive T cells and neutrophil-derived marker 
calprotectin.  The therapy, however, reduced the mucosal IL-17/CD4 cell ratio associated 
with endoscopically confirmed mucosal healing. Furthermore, the treatment was reflected 
as a decreased IL-17/Foxp3 cell ratio, which may indicate an improved balance between 
effector and regulatory T cells as a consequence of treatment.  Although these results may 
be biased by our small number of patients and sampling error, it seems that TNFα-blocking 
agents failed to normalize the mucosal IL-17 or IFN-γ upregulation characteristic of CD 
(Hölttä et al 2008). This is in keeping with what is known from clinics: TNF-blocking 
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agents (or any other known therapy at present) do not cure the disease even though they 
heal the mucosa. Relapse is very probable after discontinuation of the drug. Although 
mucosal healing is difficult to achieve, it should become the target of CD treatment. 
Rutgeerts, Vermeire, and Van Assche have recently concluded:  
“The future starts now, and we should raise the bar for our treatment goals as listed 
below: induction and maintenance of remission without steroids, complete healing of the 
intestinal and colonic mucosa, avoidance of complications and surgeries, avoidance of 
cancer, and avoidance of mortality” (Rutgeerts et al 2007).  For detection of mucosal 
healing, a need exists in clinical practice and research for surrogate markers such as 
calprotectin and lactoferrin. 
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Conclusions 
Crohn´s disease is a lifelong chronic disease with a relapsing course. Symptoms sometimes 
fail to correlate with intestinal inflammation, and repeated examinations are needed to 
detect mucosal inflammation. In CD, our study showed that fecal calprotectin and 
lactoferrin correlate closely with the validated endoscopic scores. These markers were 
significantly higher in endoscopically or clinically active than in inactive disease.  A cutoff 
concentration of 200 μg/g for calprotectin and of 10 μg/g for lactoferrin were specific in 
detecting endoscopically active disease, but sensitivity was lower. Accordingly, a cutoff 
concentration of 1000 μg/g for calprotectin and of 50 μg/g for lactoferrin for 
endoscopically moderately or severely active disease were highly specific.  
     Fecal markers correlated also with histologic scores of CD in ileocolonic or colonic 
disease. A normal calprotectin or lactoferrin value was a useful surrogate marker of 
histologically inactive disease. During anti-TNFα therapy, changes in fecal-marker 
concentrations failed, however, to correlate with changes in histologic scores. 
    Fecal calprotectin and lactoferrin were significantly higher in endoscopically active 
ileocolonic or colonic CD than in inactive disease. Both fecal markers were also higher in 
active ileocolonic or colonic CD than in active ileal disease. Furthermore, fecal markers 
failed to correlate with ileal endoscopic or histologic activity in ileal disease. In ileal 
disease with limited extension, fecal markers may thus not be as good surrogate markers of 
disease activity as in other CD locations.  
     Fecal markers correlate more strongly with endoscopic findings than does the CRP, 
widely used in follow-up of CD patiens. Measurements of either calprotectin or lactoferrin 
in follow-up of CD patients could be included in everyday clinical work.  
    During anti-TNFα therapy, both fecal markers decreased significantly and correlated 
with changes in endoscopic score. Furthermore, in patients achieving endoscopic 
remission, fecal markers normalized. Based on this study, fecal neutrophil-derived proteins 
serve well as surrogate markers of mucosal healing and are objective measures of disease 
activity. Serial fecal-marker measurements during therapy may replace endoscopic follow-
up. 
During anti-TNFα therapy, mucosal IL-17/CD4 and IL-17/Foxp3 ratios decreased, 
possibly indicating an improved balance between effector and regulatory T cells. 
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